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General introduction to norovirus 
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Book chapter in: Foodborne viruses and prions and their significance for public health, 2013, p.41-60
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Nature Reviews Microbiology, Volume 14, Issue 7, 23 May 2016
1.   Centre for Research Infectious Diseases Diagnostics and Screening, national institute for 
public health, Bilthoven, the Netherlands
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The majority of all non-bacterial gastroenteritis outbreaks are caused by 
human noroviruses and norovirus infection is associated with 18% of all cases 
of gastroenteritis worldwide[1, 2]. These viruses are highly infectious, as even a 
few particles can cause disease, and infected individuals shed high loads of 
virus[3, 4]. Transmission occurs by the faecal–oral route, either through contact 
with infected individuals or through exposure to contaminated food and water 
or to infectious aerosols that are produced by vomiting[5-8]. As a result of this 
high infectivity and efficient transmission, newly emerged strains of norovirus 
can cause global epidemics[9]. Norovirus infections are self-limiting in healthy 
individuals but are associated with severe complications in immunocom-
promised individuals, the elderly and young children[10-14].
Classification
The genus Norovirus belongs to the family of Caliciviridae and four other genera in 
this family are recognised by the International Committee on Taxonomy of Viruses 
(ICTV), i.e. Sapovirus, Vesivirus, Lagovirus and Nebovirus. The genera Vesivirus and 
Lagovirus contain some important veterinary pathogens such as feline calicivirus 
(vesivirus) and rabbit hemorrhagic disease virus (lagovirus)[15, 16]. With the exception 
of an anecdotal zoonotic vesivirus infection, only members of the noroviruses and 
sapoviruses have been found to infect humans. Sapoviruses mainly cause mild 
gastroenteritis in children up to 5 years of age, while norovirus can infect humans 
in all age groups[2, 17]. The Norovirus genus is divided in seven genogroups, which 
are further subdivided into approximately 40 genotypes (figure 1)[18]. 
Figure 1 ORF1 and ORF2 phylogenies. Two regions of the norovirus genome are used to classify 
strains of norovirus: the region of ORF1 that encodes the RNA-dependent RNA polymerase (RdRp), 
and ORF2, which encodes the structural capsid protein VP1. Genetic diversity and frequent recom-
bination events between ORF1 and ORF2 have resulted in phylogenetic topologies that, although 
similar, are not identical, as shown in unrooted maximum likelihood trees estimated for ORF1 (part 
a) and ORF2 (part b) sequences of all norovirus ORF1 and ORF2 genotypes[18]. Owing to the frequent 
occurrence of recombination events between ORF1 and ORF2 sequences, a dual nomenclature for 
norovirus classification using both sequences encoding RdRp and sequences encoding VP1 has been 
proposed[120]. Note that the nomenclature of genogroups GIV, GVI and GVII has not been consistent: 
genogroups GIV and GVI were initially classified as a single genogroup, which was known as geno-
group GIV, and norovirus strains in genogroup GVII have also been classified in the past as belonging 
to genogroup GVI. However, we have chosen to use seven genogroups, as proposed by Vinjé[18]; this 
reclassification is based on amino acid divergence. The scale bar reflects the number of nucleotide 
substitutions per site. Part b is modified from J. Clin. Microbiol., 2015, 53, 373–381, http://dx.doi.
org/10.1128/JCM.01535-14 and amended with permission from American Society for Microbiology.
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Figure 2 The composition and life cycle of human noroviruses. The norovirus genome has three 
ORFs, which encode a polyprotein — encompassing six individual non-structural proteins — and 
the structural proteins VP1 and VP2. The genome, in the form of a positive-sense RNA strand ((+)
RNA), is encapsulated in a capsid that is formed by VP1 and VP2. The capsid attaches to the cell 
surface through interactions between VP1 and host histo-blood group antigens (HBGAs) (step 
1), and is subsequently internalized, uncoated and disassembled (steps 2,3). The (+)RNA is then 
transcribed and translated in the cytoplasm of the host cell. Translation is mediated by host trans-
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Figure 3 X-ray structure of (a) the Norwalk virus capsid and (b) capsid subunit structure (figure 3 
was kindly provided by B.V.V. Prasad, Baylor College of Medicine, Houston, TX, USA). NTA = N-ter-
minal arm; P1 and P2 = P1 and P2 subdomains; S = S domain. 
lation factors that are recruited by the non-structural virus protein VPg, which covalently binds to 
the 5’end of the genome (step 4). The polyprotein that is encoded by ORF1 is post-translationally 
cleaved (step 5) by the virus-encoded protease, Pro (also known as NS6 or 3Clike), into individual 
proteins: p48 (also known as NS1/2 or Nterm), NTPase (also known as NS3 or 2Clike), p22 (also 
known as NS4 or 3Alike), VPg, Pro and RNA-dependent RNA polymerase (RdRp). During genome 
replication, (+)RNA is transcribed into negative-sense RNAs ((–)RNAs), which are used as templates 
for the synthesis of new genomic and subgenomic (+)RNAs, respectively (step 6). Subgenomic 
(+)RNAs contain only ORF2 and ORF3, and are used for the production of VP1 and VP2. During 
encapsidation (step 7), genomic — and possibly subgenomic — (+)RNAs are packaged into new 
virions, which are subsequently released from the infected host cell (step 8), although the mecha-
nism by which release occurs remains largely unknown.
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Genome organisation
Noroviruses have a positive linear single-stranded RNA genome with a size of 
approximately 7.5 kb that is organised in three open reading frames (ORF’s) 
(figure 2). ORF1 encodes for a polyprotein containing all seven non-structural 
proteins that is produced as one large polyprotein and then cleaved into individual 
proteins[19]. The non-structural proteins are essential for the production of new 
viruses in infected cells but do not form part of virus particles. ORF2 encodes 
the major structural protein VP1 (alternative name: capsid protein) and ORF3 
encodes the VP2 protein (or minor capsid protein). The VP2 protein is assumed 
to be a minor structural protein since each norovirus virion only contains one 
or two copies[20]. During replication of the RNA genome, the RNA-dependent 
RNA polymerase does not have a complementary strain for proofreading activity. 
Therefore, noroviruses, like other RNA viruses, have a high mutation rate of 
1-4 x 10-3 substitutions per nucleotide per year, while DNA-dependent DNA 
polymerases (DNA viruses or cellular organisms) have a mutation rate of 1 x 
10-6 - 10-8 substitutions per nucleotide per year[21, 22]. Hence, RNA viruses are 
highly diverse and have a much faster evolution rate compared to their host[23]. 
Due to this high mutation rate, a norovirus population in a single host exists of a 
diverse mixture of nearly identical strains (quasi-species). This property, common 
to several RNA viruses, calls for the genetic flexibility of these viruses. 
Virus characteristics 
Noroviruses do not have a lipid envelope, but the genetic material is protected 
by a capsid of VP1 proteins. With this capsid noroviruses can survive the acidic 
environment of the stomach and persist for a long period in the environment, 
although the particles appear to be less stable at elevated pH[4]. The VP1 protein 
is the major structural protein of norovirus and each virion contains 180 copies 
(90 dimers) of the VP1 protein symmetrically arranged (figure 3). The virus 
attaches with the VP1 protein to the host cell receptor and VP1 therefore plays 
an important role in virus-host interactions[24]. Cryo-electron microscopy studies 
have shown that the VP1 protein can be divided in two pieces: the shell domain 
and the protruding domain (S and P domain) (figure 3). All S-domains of the 180 
VP1 copies form a shell around the viral RNA (icosaheder) and the P domains 
form arch-like structures surrounding the shell. The P domain is connected to 
the S-domain via a flexible hinge and can be further subdivided in the P1 and P2 
domain of which P2 mostly protrudes[25].
Virus shedding and infectivity
Noroviruses enter the body via the mouth and virions pass the acidic 
environment of the stomach. Replication takes place in the upper intestinal 
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tract, but the exact cell type is unknown[26]. Virions are shed in high quantities 
(107-1010 RNA copies per gram) in faeces[27-30] and have been detected with lower 
loads in vomitus as well[31]. Infected individuals shed virus in highest quantities 
during the acute phase and shedding continues during an asymptomatic phase 
which can last 9-56 days[3, 27]. Prolonged and asymptomatic shedding has been 
reported for children (up to 100 days) and immunocompromised patients can 
suffer from prolonged illness and shedding, which can last up to several years[14, 
29, 32-35].
Norovirus is highly infectious with an estimated basic reproduction number (R0) 
of more than 14 during an outbreak in a scouting camp[36], which means that 
during the infection period each case, on average, has infected 14 other cases. 
The implementation of hygiene measures on the scouting camp had a large 
effect on the R0, which decreased to 2
[36]. This high R0 is in part explained by the 
low dose required for infection. Therefore, even removal of several logs of virus 
during contamination events may still not be enough to stop spread of disease[37].
Incubation period and symptoms 
In healthy individuals, norovirus causes mild gastroenteritis and symptoms 
are generally self-limiting. From outbreak studies it is known that symptoms 
usually last < 1-5 days and include vomiting, non-bloody diarrhoea, abdominal 
cramps and pain, nausea, and fever[38-40]. In children, vomiting is more common 
whereas adults endure more often diarrhoea[40]. Norovirus outbreaks tend to 
have a longer incubation period compared to bacterial gastroenteritis outbreaks. 
In 85% of norovirus outbreaks, the incubation period was > 24 h compared 
to 39% for outbreaks caused by a bacterial agent[41]. In 1982, Kaplan et al. 
reviewed 642 acute gastroenteritis outbreaks to extract criteria for identifi-
cation of Norwalk-like associated outbreaks[42]. These Kaplan’s criteria are 1) 
> 50% of cases vomits, 2) mean or median incubation period of 24-48 hours 
post infection, 3) duration of illness between 12 and 60 h, and 4) absence of 
etiological bacteria in stool samples. In 2006, these criteria were re-assessed 
and revealed to be highly specific (99%), moderately sensitive (68%) and a 
useful diagnostic tool to distinguish norovirus outbreaks from bacterial outbreaks 
in outbreak situations where other diagnostic methods are not yet available[43]. 
Transmission 
Surveillance through national and international collaborative networks, such 
as CaliciNet and NoroNet, has provided important insights into how different 
strains of human norovirus correspond to modes of transmission and outbreak 
settings. Strains of the GII.4 genotype caused 70–80% of all reported outbreaks 
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over the past 13 years or so[44], but the prevalence of infecting genotypes differs 
between human populations and routes of transmission[45]. Genotype GII.4 is 
more often associated with transmission mediated by person-to-person contact 
than with other types of transmission, whereas non-GII.4 genotypes, such 
as GI.3, GI.6, GI.7, GII.3, GII.6 and GII.12, are more often associated with 
foodborne transmission[6]. GI strains are more often associated with waterborne 
transmission than GII strains[8], a trait that may relate to the proposal that GI 
strains have a higher stability in water than GII strains. As strains may adapt to 
host factors that vary according to the population that is infected, such as age, 
health and pre-existing immunity, differences in the epidemiology of norovirus 
genotypes in community settings are likely to influence the evolution of the 
genotypes. 
Foodborne transmission is an important route for the global spread of 
noroviruses[6] and can occur either when food handlers contaminate food on 
site or during the earlier steps of food production[46]. For example, shellfish that 
are cultivated in coastal areas can be contaminated by faecal discharge[47], and 
products such as fresh and frozen berries can be contaminated by irrigation 
with sewage-contaminated water or by contact with infected personnel during 
harvesting and processing. Foodborne outbreak events occur frequently and are 
a potential source of transmission of strains between different parts of the world, 
given the globalization of the food chain. These outbreaks can include mixtures 
of norovirus strains[8], thus increasing the risk of viral recombination. The global 
scale of foodborne outbreaks of noroviruses can be difficult to recognize because 
the epidemiology of outbreaks is often tracked independently by individual 
countries; nonetheless, retrospective studies have shown that approximately 
7% of foodborne outbreaks of noroviruses are part of an international event 
with a common source[48]. Globally, noroviruses rank among the top causes of 
foodborne disease[49]. 
Nosocomial transmission of noroviruses in hospitals is a major burden for 
inpatient services[2]. Individuals may shed norovirus particles in considerable 
numbers for several weeks after the resolution of symptoms[39], possibly acting 
as a source for nosocomial transmission[50]. However, analyses of nosocomial 
outbreaks suggest that most of these outbreaks are the result of transmission 
from symptomatic shedders[50]. In a hospital setting, immunocompromised 
patients who are chronically infected with norovirus and are symptomatic can 
act as a reservoir of the virus and may contribute to nosocomial transmission[51, 
52]. As a consequence of prolonged shedding and limited immune pressure, these 
immunocompromised patients can harbour numerous norovirus variants. The 
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intrahost viral variation in a chronic shedder can mimic the antigenic variations 
that are seen between consecutive human norovirus pandemics, and some of 
these variants may be able to escape herd immunity[53].
Infections of humans with animal norovirus strains have not yet been reported, 
but there is some evidence for the transmission of noroviruses between different 
host species. Human noroviruses have been detected in the stool of pigs, cattle 
and dogs[54, 55], and gnotobiotic calves and pigs can become experimentally 
infected with human GII.4 strains[56, 57]. Furthermore, canine seroprevalence to 
different human norovirus genotypes resembles the seroprevalence in the human 
population[58], and serum antibodies against bovine and canine noroviruses have 
been detected in humans, with higher levels in veterinarians than in the general 
population[59, 60]. 
Virus detection
Norovirus was discovered in 1972 by Electron Microscope (EM) analysis of stool 
samples from an outbreak of acute non-bacterial gastroenteritis with unknown 
aetiology at an elementary school in Norwalk, Ohio[61]. EM can visualize 
norovirus particles, but because the concentration of particles required for 
reliable detection by EM is estimated to be around 105 or higher, it is relatively 
insensitive compared to molecular methods. The time of sampling is critical 
for a successful diagnosis with EM. In 11 of 23 norwalk challenged volunteers, 
virions could be detected in at least one specimen within 72 hours after onset of 
disease [62]. Before the onset of disease all specimens were negative and after 72 
hours post challenge only 2 of 11 specimens were positive. 
Reverse transcriptase polymerase chain reaction (RT-PCR) is nowadays the 
most frequently used technique for detection of norovirus RNA in stool samples. 
RT-PCR uses a reverse transcriptase enzyme to reverse transcribe RNA into 
cDNA (complementary DNA). The cDNA molecules are subsequently amplified 
and quantified using a fluorescent dye. Various RT-PCR assays are developed 
for norovirus detection in clinical samples like faeces and vomitus, in food 
samples, and environmental samples. Due to the high sequence variability 
among norovirus strains, most RT-PCR assays use primers that target a 
conserved region in ORF1 (coding for the viral RNA polymerase) or a conserved 
region in the ORF1-ORF2 junction region[63, 64]. Although sensitivity of these 
assays for detection of viruses from different genotypes may differ, this problem 
seems to have been overcome in more recent PCR protocols[65]. Nevertheless, 
the potential differences in sensitivity of diagnostic assays should always be 
considered in gastroenteritis outbreak situations that fulfil Kaplan’s criteria, 
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but without positive PCR results. Of note: this may be particularly the case in 
foodborne disease outbreaks, where less common genotypes are seen[66]. This 
also explains why genotyping may be important in outbreak investigations.
Immunoassay (EIA) like i.e. IDEIA Norovirus (Thermo Fisher Scientific, 
Basingstoke, United Kingdom), RIDASCREEN Norovirus (R-Biopharm, 
Darmstadt, Germany) and SRSV(II)-AD (Denka Seiken Co. Ltd., Tokyo, Japan) 
are available to detect norovirus antigen in stool samples. The advantage of 
EIA assays compared to RT-PCR based methods is the simplicity and rapidity 
of the assay. No specialised equipment is required and results can be ready 
within four hours. These three assays make use of a sandwich ELISA format. 
The SRSV(II)-AD and IDEIA assays use monoclonal antibodies against GI 
and GII to capture the norovirus antigens in stool samples[67, 68]. Horseradish 
conjugated rabbit polyclonal antibodies directed against a pool of GI and GII 
VLP’s are subsequently added to detect the antigens. Not much is known about 
the reagents used for the RIDASCREEN assay, but it has been described that 
it does make use of monoclonal antibodies for antigen capture and a secondary 
antibody for antigen detection[69]. Comparative studies have tested sets of 
stool samples with the commercial ELISA assays and showed a wide range of 
sensitivity and specificity values. Among these studies the median sensitivity 
was 56% (range: 31-92) and median specificity of 95% (range: 47-100%) 
depending on the type of assay and strains tested[67, 68, 70-75]. This low sensitivity 
precludes use of these assays for individual patients, but diagnosis of outbreaks 
may be possible[76]. Nevertheless, due to the high genetic and antigenic diversity 
of norovirus strains, certain genotypes can be missed with these assays and 
therefore they should preferably be used in combination with a confirmation of 
negative samples by RT-PCR.
Host immune response
Why norovirus infections can result in severe complications and chronic 
infections in certain high-risk groups is not fully understood, as the factors that 
offer protection to the host during infection with human noroviruses are not fully 
known. For murine noroviruses, components of the adaptive immune system, 
including B cells, CD4+ T cells and CD8+ T cells, are required for efficient 
viral clearance from the intestine and intestinal lymph nodes[77]. In addition 
to the adaptive immune system, the innate immune system seems to have an 
important role in the clearance of infection. 
Early studies of infection in humans suggested that the acquisition of protective 
immunity to noroviruses is short term[78], but more recent reports indicate that 
protective immunity is longer lasting than initially thought[79, 80]. Owing to the 
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historical lack of a cell culture system for the study of norovirus replication, 
virus neutralization has not been measured directly and the measurement of 
the inhibition of VLP binding to HBGAs has instead been used as a surrogate 
assay [81]. In challenge studies in humans and chimpanzees, increased serum 
titres of antibodies that inhibited VLP binding to HBGAs correlated with 
a reduction in the rate of infection and in disease severity[82, 83]. In human 
challenge studies, an early mucosal immunoglobulin A (IgA) response was 
associated with protection against norovirus infection[84]. Furthermore, pre-ex-
isting norovirus-specific IgA in saliva and norovirus-specific memory IgG cells 
were associated with protection from gastroenteritis[85]. Moreover, pre-existing 
faecal norovirus-specific IgA was associated with a reduction in peak viral load, 
and the magnitude of faecal levels of IgA measured one week after infection 
correlated with a shorter duration of shedding[85]. In conclusion, these findings 
support a role for host immune responses in reducing the viral load, the duration 
of virus shedding and the severity of disease. 
Attachment to histo-blood group antigen variants 
HBGAs are glycans that are expressed on the surface of specific cells — and 
present in saliva and other bodily secretions — and are determinants of both 
the ABO blood group and Lewis blood group systems[86]. In certain cell types, 
α(1,2)-fucosyltransferase 2 (FUT2; also known as galactoside 2αlfucosyltrans-
ferase 2) adds a fucose group to precursors of HBGAs, generating H HBGAs, 
and subsequent reactions generate A and B HBGAs. The binding specificity 
of norovirus VP1 to different HBGAs differs among norovirus genotypes and 
genogroups[87], resulting in differences in the susceptibility of human individuals 
to specific strains of norovirus[84, 88]. Individuals who lack FUT2 are known as 
non-secretors, as A, B and H HBGAs are not present in the bodily secretions of 
these individuals[89]. Around 20% of Northern Europeans are non-secretors[88], 
and children of Mesoamerican ancestry are more likely to be secretors than 
children of European or African ancestry[90]. Non-secretors have been shown to 
be less susceptible to infection with several GI and GII strains of norovirus[84, 88, 91]. 
Differences in the expression of HBGAs have a major effect on the susceptibility 
of individuals to norovirus infections and on the pathogenesis of norovirus strains, 
as shown in several studies, including a human challenge study with a norovirus 
GII.4 Farmington Hills 2002 strain. In healthy adults, challenge resulted in the 
infection of 70% of those individuals with a functional FUT2; of these, 57% 
developed symptoms of infection. By contrast, only a single individual (6%) was 
infected in the group without a functional FUT2, and this individual displayed 
minimal disease[92]. The HBGA specificities of norovirus genotypes, including 
GII.4 strains, have been comprehensively reviewed elsewhere[93, 94].
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Genetic diversity and evolution 
Viruses in the genus Norovirus can be found in a wide range of hosts, such as 
humans, rodents, felines, canines, sea lions, pigs, sheep, cattle and bats[18, 95, 
96] (figure 1). The nucleotide sequences of the genomes of different norovirus 
genogroups share only 51–56% similarity with one another, and the diversity 
between genogroups is even higher when comparing only ORF2 sequences 
rather than whole genomes[87, 97]. Despite frequent recombination and possible 
differences in selection pressures between ORF1 and ORF2, the phylogeny 
of ORF1 has a similar topology and a similarly high genetic diversity to the 
phylogeny of ORF2[18] (figure 1). Intriguingly, some outbreaks are caused by 
strains of norovirus that are genetically similar or identical to strains that were 
isolated 10–15 years earlier, which raises questions about the reservoirs in 
which these viruses are maintained between outbreaks[8]. Surveillance studies 
have shown that globally circulating GII.4 strains are frequently replaced by 
newly emerged antigenically divergent GII.4 strains, which indicates that an 
immunogenic pressure influences the evolution of noroviruses, at least for the 
GII.4 genotype[87]. Importantly, the emergence of antigenically divergent GII.4 
strains coincides with an increase in norovirus outbreak activity[98]. Bioinformatic 
analyses and in vitro assays have shown that GII.4 strains have high rates 
of mutation and evolution, which probably facilitate the emergence of these 
antigenically divergent strains[99]. Molecular epidemiology of GII.4 isolates 
collected across the globe showed that some GII.4 lineages that are able to 
cause widespread regional epidemics were nevertheless geographically limited[9]. 
The failure of these epidemics to spread throughout the world could be due to 
differences in the genetic and microbial makeup of the host or differences in the 
previous exposure of host populations to noroviruses. Since 1995, six antigen-
ically variant GII.4 strains have resulted in pandemics: US 1995/96, Farmington 
Hills 2002, Hunter 2004, Den Haag 2006b, New Orleans 2009 and Sydney 
2012[100]. The emergence of the Farmington Hills antigenic variant in 2002 
coincided with an increase in the number of reported norovirus outbreaks[101], 
which was confirmed by phylodynamic reconstruction to reflect a true increase 
in infections rather than reporting bias[98]. 
Prevention 
In health care institutions, outbreak management focuses on preventing 
further spread of the virus by containment of infected individuals and hygienic 
measures. Hand washing with antiseptic soap for 10 seconds is the key hygienic 
measure and has demonstrated to prevent further spread of health-care 
associated infections (bacteria and viruses)[102]. Evidence for effect of hand 
disinfectants on infectivity is difficult to obtain, because the human noroviruses 
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cannot be grown in cell culture and animal noroviruses and caliciviruses 
have different properties[103]. Hand washing with ethanol based solutions or 
wipes have shown not to be effective for significantly reducing viral concen-
tration[102]. Noroviruses are very stable on environmental surfaces, like water 
taps, door-handles or cutting plate, and require chemical disinfection with 
high concentration of hypochlorite, detergents based on hydrogen peroxide or 
phenolic-based cleaning solutions[37, 104-106].
Clinical intervention efforts for norovirus infection are hampered by the lack 
of a licensed vaccine, despite important advances in vaccine development, 
and limited evidence for the success of the antiviral treatment options that 
are currently available. Several individuals who were chronic shedders have 
been successfully treated with oral human immunoglobulin, although in some 
patients treatment did not result in clearance of the virus[107, 108]. Additional 
studies will be required to determine whether the route of administration 
and/or the levels of antibodies that are specific to the infecting strain of 
norovirus are important factors in the success rate of human immunoglobulin 
treatment. The ability of immunoglobulin to limit infection was also seen in a 
mouse model of norovirus infection following intraperitoneal administration 
of immunoglobulin[109]. Another strategy that may clear norovirus infections in 
immunocompromised patients is the partial restoration of the immune system, 
whether by reducing, temporarily discontinuing or changing immunosuppressive 
drugs[110]. However, this should be done with caution, and is not possible for all 
patients. 
Antivirals, including nitazoxanide, ribavirin and interferons, have been shown 
to inhibit norovirus replication in cell culture-based replicon systems, mouse 
models or infected human individuals[111-116]. Oral treatment with nitazoxanide, an 
agent that has broad antimicrobial activity, resulted in clinical resolution of acute 
gastroenteritis in a patient who was chronically infected, although asymptomatic 
shedding was observed for another month[113]. Nitazoxanide also reduced the 
duration of symptoms in a small randomized, double-blind, placebo-controlled 
clinical trial[112]. Two chronically infected immunocompromised individuals were 
successfully treated with oral ribavirin, which is a broad-spectrum antiviral 
agent, although a similar treatment was unsuccessful in two other patients[114]. 
Historically, the development of a norovirus vaccine has been hampered by 
the lack of a small-animal model and a cell culture system, both of which have 
been described only recently, and licensed vaccines are not yet available[117]. 
Nevertheless, the first norovirus vaccines have now completed Phase I and 
Chapter 1
20
1
Phase II clinical trials[117]. These vaccines are based on VLPs of the GI.1 genotype 
or, in the case of the bivalent vaccine, contain both GI.1-derived VLPs and VLPs 
based on the consensus sequence of several GII.4 variants[117]. The clinical trials 
showed an induction of antibody responses that occurred regardless of whether 
the vaccine was administered intramuscularly, orally or intranasally[118]. In a 
clinical trial with healthy volunteers, intramuscular vaccination with bivalent 
VLPs did not significantly reduce the incidence of protocol-defined illness after 
challenge with a GII.4 strain of norovirus. However, the vaccination was able to 
reduce the incidence and severity of vomiting and diarrhoea[119]. 
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Scope of the thesis
The aim of this thesis was to get a better understanding of the global norovirus 
diversity, with a focus on the role of chronic norovirus infection on virus 
diversity, antigenic variation and evolution. The obtained knowledge can be used 
to predict severe norovirus outbreak seasons, is useful for hospital hygiene and 
infection control guideline improvement, and is important for future vaccine 
development.
We first describe major changes in the global norovirus diversity. In chapter 2.1 
the emergence of the GII.4 Sydney 2012 variant is described and in chapter 2.2 
we describe the emergence of GII.17 and replacement of GII.4 in Asia, and the 
possible consequences for the global public health community. In chapter 3 we 
show an integrated analysis of 10 years molecular and epidemiological norovirus 
surveillance via the international NoroNet network and describe a future 
perspective on norovirus surveillance. 
Recent changes in the norovirus diversity raises questions on the norovirus 
prevalence before the introduction of molecular techniques for norovirus 
detection. Since historical faecal sample collections are exceedingly rare, we 
developed a multiplex serological assay for the detection of norovirus antibodies 
in human serum samples and used this assay to study the norovirus seroprev-
alence in historical and recent serum collections (chapter 4).
Chronic norovirus infection is a recently described phenomenon among 
immunocompromised patients and it has been hypothesized that chronic 
infection plays a role in the development of new norovirus drift variants. In 
chapter 5 we study the prevalence of chronic norovirus infection among 
solid organ transplant recipients in a tertiary care hospital. In chapter 6 we 
investigated the genetic and antigenic changes, and quasi species diversity 
of the within-host virus population among longitudinal samples of patients 
with chronic norovirus infection by using next-generation deep sequencing 
technology.
In chapter 7 we summarize the findings of this thesis and discuss the results in 
relation to other (recent) norovirus scientific publications. 
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Abstract
Globally, surveillance systems showed an increase in norovirus activity in late 
2012. Molecular data shared through the NoroNet network suggest that this 
increase is related to the emergence of a new norovirus genotype II.4 variant, 
termed Sydney 2012. Healthcare institutions are advised to be prepared for a 
severe norovirus season.
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In the United Kingdom (UK), the Netherlands, and Japan, norovirus (NoV) 
epidemiological and laboratory surveillance systems show increased levels of 
NoV activity compared to previous seasons, in late 2012[1-3]. Similarly, increases 
have been noted in Australia, France and New Zealand (unpublished data). 
At this stage, and with the limited surveillance of NoV in most countries, it is 
difficult to conclude if these increases denote early seasonal activity or truly 
increased incidence, although for the UK the latter has been suggested. On 
29 November, and on 4 and 6 December, ProMed (http://www.promedmail.
org/) messages reported a dramatic rise in NoV hospital outbreaks in England, 
a 64% higher number of confirmed NoV laboratory reports (hospital- and 
community-acquired) in England and Wales, and NoV-related deaths in elderly 
in Japan. The first molecular data uploaded to the international molecular 
surveillance database NoroNet from Australia, France, New Zealand and 
Japan indicate that this increase is associated with emergence of a new variant 
of genotype II.4 (GII.4). The first report of this variant was from Australia in 
March 2012 (personal communication P.A. White, September 2012), and the 
strain sequence was submitted to GenBank (accession number: JX459908.1). 
In the United States (US), the variant (named Sydney 2012) was detected in 
September 2012 in five of 22 (23%) laboratory-confirmed outbreaks, and in 
November in 37 of 71 (52%) laboratory-confirmed outbreaks (recorded in the 
US norovirus surveillance network CaliciNet)[4]. In two European countries that 
have not reported any indications of increased activity, the new variant has been 
found in outbreaks, two in Belgium (September and December 2012) and one in 
Denmark (November 2012). Other countries participating in NoroNet have not 
yet reported the new variant.
NoV is the predominant aetiological viral agent of acute gastroenteritis 
worldwide and is present throughout the year, but most prevalent in the winter 
season in temperate climates. In the last decade, strains belonging to NoV GII.4 
have been responsible for the majority of outbreaks, as well as community cases 
of acute gastroenteritis. It has been suggested that hospitalisation and deaths 
occur more frequently during peak seasons associated with new NoV GII.4 
variants[5-7]. Since 1995, new epidemic variants of GII.4 have emerged every two 
to three years, with population immunity and genetic drift as major evolutionary 
driving forces[8]. Emergence of new variants has been associated with increased 
NoV activity early in the season[9-11]. The newly found NoV GII.4 Sydney 2012 
variant has evolved from previous NoV GII.4 variants (figure 1) and will be 
described in detail elsewhere. Briefly, the NoV GII.4 Sydney 2012 variant has 
a common ancestor with the dominant NoV GII.4 variants Apeldoorn_2007 
and NewOrleans_2009, but is phylogenetically distinct. Amino acid changes 
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Figure 1 Neighbour-joining tree of norovirus GII.4 capsid amino acid sequences
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are seen in the main epitopes located at the P2 domain, consistent with 
observations from prior epidemics. This may have led to an escape to existing 
herd immunity and might explain the observed increased outbreak activity.
The reference set of the Norovirus Typing Tool has been updated to correctly 
assign GII.4 Sydney 2012 sequences. This web-based tool (http://www.rivm.nl/
mpf/norovirus/typingtool) is publicly available for genotyping of NoV sequences 
and was developed to facilitate standardisation of nomenclature[12].
Conclusion
Various countries around the globe have reported a higher incidence of NoV 
outbreaks or illness late 2012, and the first molecular data available via NoroNet 
suggests that this increase is related to emergence of a new variant of NoV 
GII.4. More data is needed to confirm the association between a higher NoV 
incidence and the new NoV GII.4 2012 variant. For this, we invite new members 
to join the NoroNet network (http://www.noronet.nl). Noronet is a worldwide 
network for NoV molecular and epidemiological surveillance, through which 
countries in Europe, Asia, and Australasia have shared NoV outbreak data, 
sequences, and other information. The NoroNet database, including analysis 
tools, is accessible for all NoroNet members.
With the early signs of a severe NoV season, healthcare institutions are advised 
to be prepared for NoV introductions. Outbreak management measures, like 
stringent hygiene measures and quarantine of infected cases, can help to reduce 
the size of outbreaks[13,14]. 
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Abstract
In the winter of 2014/15 a novel GII.P17-GII.17 norovirus strain (GII.17 
Kawasaki 2014) emerged, as a major cause of gastroenteritis outbreaks in China 
and Japan. Since their emergence these novel GII.P17-GII.17 viruses have 
replaced the previously dominant GII.4 genotype Sydney 2012 variant in some 
areas in Asia but were only detected in a limited number of cases on other 
continents. This perspective provides an overview of the available information 
on GII.17 viruses in order to gain insight in the viral and host characteristics 
of this norovirus genotype. We further discuss the emergence of this novel 
GII.P17-GII.17 norovirus in context of current knowledge on the epidemiology 
of noroviruses. It remains to be seen if the currently dominant norovirus strain 
GII.4 Sydney 2012 will be replaced in other parts of the world. Nevertheless, the 
public health community and surveillance systems need to be prepared in case 
of a potential increase of norovirus activity in the next seasons caused by this 
novel GII.P17-GII.17 norovirus. 
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Introduction
In this issue of Eurosurveillance, observations from Japan are reported on an 
unusual prevalence of a previously rare norovirus genotype, GII.17, in diarrheal 
disease outbreaks at the end of the 2014/15 winter season[1], similar to what was 
observed for China[2, 3]. Norovirus is a leading cause of gastroenteritis[4]. Although 
the infection is self-limiting in healthy individuals, clinical symptoms are much 
more severe and can last longer in immunocompromised individuals, the elderly 
and young children[5, 6]. 
The Norovirus genus comprises seven genogroups (G), which can be subdivided 
in more than 30 genotypes[7]. Viruses belonging to the GI, GII and GIV 
genogroups can infect humans, but since the mid-1990s GII.4 viruses have 
caused the majority (ca 70–80%) of all norovirus-associated gastroenteritis 
outbreaks worldwide[8-10]. 
GII.4 viruses can continue to cause widespread disease in the human population 
because they evolve through accumulations of mutations into so-called drift 
variants that escape immunity from previous exposures[11]. Contemporary GII.4 
noroviruses also demonstrate intra-genotype recombination near the junction of 
open reading frame (ORF) 1 and ORF2, which is likely to foster the emergence of 
novel GII.4 variants[12]. In addition, the binding properties of GII.4 viruses have 
altered over time, resulting in a larger susceptible host population[13].
Emergence and geographical spread of GII.17 genotype noroviruses
Viruses of the GII.17 genotype have been circulating in the human population for 
at least 37 years; the first GII.17 strain in the National Center for Biotechnology 
Information (NCBI) databank is from 1978[14]. Since then viruses with a GII.17 
capsid genotype have sporadically been detected in Africa, Asia, Europe, North 
America and South America (Table, Figure 1). The virus appears to be clinically 
relevant, as it has been associated with acute gastroenteritis (AGE) in children 
and adults, and with chronic infection in an immunocompromised renal 
transplant patient[15] and a leukaemia patient (unpublished data). In the United 
States (US), only four GII.17 outbreaks were reported between 2009 to 2013 
through CaliciNet, with a median of 11.5 people affected by each outbreak[16]. In 
Noronet, an informal international network of scientists working in public health 
institutes or universities sharing virological, epidemiological and molecular data 
on norovirus, GII.17 cases were also sporadically reported in Denmark and South 
Africa during this period[17].
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Sporadic detection of the novel GII.17 virus
The novel GII.17 is the predominant genotype Major outbreaks of the novel GII.17 virus
Sporadic detection of GII.17 viruses from before the emergence of the novel GII.17 virus
Detection of the novel GII.17 virus in environmental samples
Figure 1 World map showing areas where GII.17 norovirus strains have been detected, 1978–2015
More widespread circulation of GII.17 was first reported for environmental 
samples in Korea from 2004 to 2006. This information was published in a 
report in 2010 by the Korean Food and Drug Administration (KFDA) and was 
cited by Lee et al.[18], but the original document describing this finding is not 
publicly available and there are no matching clinical reports. From 2012 to 2013 
a novel GII.17 virus accounted for 76% of all detected norovirus strains in rivers 
in rural and urban areas in Kenya[19]. In the winter of 2014/15, genetically closely 
related GII.17 viruses were first detected in AGE outbreaks in the Guangdong 
province in China in schools, colleges, factories and kindergartens[2]. Sequence 
analyses demonstrated that 24 of the 29 reported outbreaks during that winter 
were caused by GII.17. A large increase in the incidence of AGE outbreaks was 
also reported; 29 outbreaks associated with 2,340 cases compared with nine 
outbreaks and 949 cases in the previous winter when GII.4 Sydney 2012 still 
was the dominant genotype[2].
During the same winter there was also an increase in outbreak activity in Jiangsu 
province, which could be attributed to the emergence of this novel GII.17[3]. 
This triggered us to investigate the prevalence of GII.17 in other parts of the 
world by means of a literature study and by inviting researchers collaborating 
within Noronet to share their data on GII.17. Currently, in Asia, in addition to 
Guangdong and Jiangsu[2, 3], the novel GII.17 is also the predominant genotype in 
Hong Kong (unpublished data) and Taiwan[20], while in Japan, a sharp increase 
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in the number of cases caused by this novel virus has been observed during the 
2014/15 winter season[1]. Related viruses have been detected sporadically in the 
US[21] (http://www.cdc.gov/norovirus/reporting/calicinet/index.html), Australia, 
France, Italy, Netherlands, New-Zealand and Russia (unpublished data, www.
noronet.nl) (Figure 1). In France the novel GII.17 virus appeared at the beginning 
of 2013, but since then, it has not resulted in an increase in AGE outbreaks as 
observed in China, nor replaced the predominant GII.4 in the last seasons (data 
not shown). 
Based on sequence analyses of the ORF1-ORF2 junction region, most diagnostic 
real-time transcription polymerase chain reactions (PCRs) will be able to detect 
this novel GII.17 virus, but it is not known whether the same holds true for 
immunoassays. However, only a small portion of norovirus outbreaks are typed 
beyond the GI and GII classification, therefore it is possible that GII.17 is more 
prevalent than we currently suspect.
Phylogenetic analyses and molecular characterisation of the novel GII.17 
viruses
Phylogenetic analysis of the viral protein 1 (VP1) of GII.17 strains in the NCBI 
database demonstrated at least two clusters, with the novel Asian GII.17 strains 
grouping together with the GII.17 strains detected in the surface water in Kenya 
(Figure 2,[21]) and in an outbreak in 2012 in Korea[22]. Although the novel GII.17 
clusters away from previously identified GII.17 strains, the amino acids changes 
in VP1 are not sufficient to separate it into a different genotype. For only a limited 
number of GII.17 strains the full VP1 has been sequenced, which demonstrated 
three deletions and at least one insertion compared with previous GII.17 strains 
(comprehensive alignments are given in Fu et al. and Parra et al.[3, 21]). The majority 
of these changes could be mapped in or near major epitopes of the VP1 protein 
and potentially result in antigenic drift or altered receptor-binding properties[21]. 
Most publicly available GII.17 sequences only comprise the VP1, and most 
frequently the 5’-end of VP1 (C region), while most of the observed diversity 
within the GII.17 genotype is observed in the 3’-end of VP1 (D region)[23].
Previously, viruses with a GII.17 VP1 genotype contained a GII.P13 ORF1 
genotype, although recombinants with an ORF1 GII.P16, GII.P3 and GII.P4 
genotype have also been identified (Table). Sequence comparison showed that 
the ORF1 region of the novel GII.17 viruses was not detected before and cluster 
between GII.P3 and GII.P13 viruses[21]. Since this is the first orphan ORF1 
sequence associated with GII.17, it has been designated GII.P17 according to the 
criteria of the proposal for a unified norovirus nomenclature and genotyping[24]. 
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a  GII.17 detection year(s) with study years between brackets.
b   Either the percentage of strains that was typed as GII.17 or the percentage of outbreaks that 
was caused by GII.17 is given.
c   GII.17 detection location with study location between brackets (when different from GII.17 
detection location)
d  acute gastroenteritis (AGE)
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Figure 2 Unrooted maximum likelihood phylogenetic tree based on the 5’-end of virus protein 1 
(VP1) sequences (C region) of GII.17 noroviruses, available from the National Center for Biotech-
nology Information (NCBI). The tree was estimated under the general time reversible model using 
PhyML. Bootstrap values above 70% are given. Sequences from Kenya are depicted in red and 
those from the recent outbreaks (2013–1015) reported in Asia in blue. The scale bar represents 
nucleotide substitutions per site. 
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The novel GII.17 virus was termed Kawasaki 2014 after the first near complete 
genome sequence (AB983218) submitted to GenBank. Noronet provides a 
publicly available and widely used tool for the typing of norovirus sequences 
(http://www.rivm.nl/mpf/norovirus/typingtool). This typing tool was updated 
to ensure correct classification of both ORF1 and ORF2 sequences of the newly 
emerged GII.P17-GII.17 viruses.
The acquisition of a novel ORF1 could potentially result in an increase in 
replication efficiency and may – in part – explain the increase of the AGE 
outbreak activity. Histo-blood group antigens (HBGAs) function as (co-)
receptors for noroviruses. Alpha(1,2)fucosyltransferase 2 (FUT2) adds an 
alpha-1,2 linked fucose on HBGAs, and individuals lacking the FUT2 gene 
are referred to as ‘non-secretors’, while those with a functional FUT2 gene 
are called ‘secretors’. Non-secretors have been shown to be less susceptible 
to infection with several norovirus genotypes[25]. In studies investigating the 
genetic susceptibility to norovirus genotypes, a secretor patient with blood type 
O Lewis phenotype Lea-b +  and a secretor patient with blood type B Lewis 
phenotype Lea-b- were positive for previously identified GII.17 viruses and no 
non-secretors were found positive[26, 27], suggesting that there could be genetic 
restrictions for GII.17 viruses in infection of humans. How the observed genetic 
changes have affected the antigenic and binding properties of the novel GII.17 
strains, and hereby the susceptible host population, remains to be discovered.
Public health implications
Based on the emergence and spread of new GII.4 variants, we know that 
noroviruses are able to rapidly spread around the globe[28, 29]. The novel GII.17 
virus has been detected in sporadic cases throughout the world, but until now 
it has not resulted in an increase in outbreak activity or replacement of GII.4 
Sydney 2012 viruses outside of Asia. Following the patterns observed in the 
past years for GII.4 noroviruses and based on the data from China and Japan, 
an increase in norovirus outbreak activity can be expected if the currently 
dominant GII.4 is replaced by GII.17. Another possibility – however– would 
be some restriction to global expansion, as has been observed previously for 
the norovirus variant GII.4 Asia 2003[29]. Such restrictions could be due to 
differences in pre-existing immunity, but could also be the result of differences 
between populations in the expression of norovirus receptors[29]. Based on 
current literature on the novel GII.17 virus there is no indication that it will be 
more virulent compared with GII.4. Nevertheless, the public health community 
and surveillance systems need to be prepared in case of a potential increase of 
norovirus activity by this novel GII.17 virus.
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Conclusions
Understanding the epidemiology of norovirus genotypes is important given 
the development of vaccines that are entering clinical trials. Current candidate 
vaccines have targeted the most common norovirus genotypes, and it remains 
to be seen if vaccine immunity is cross-reactive with GII.17 viruses[30]. 
Contemporary norovirus diagnostic assays may not have been developed to 
detect genotype GII.17 viruses since this genotype was previously only rarely 
found during routine surveillance. These assays need to be evaluated and 
updated if necessary to correctly diagnose norovirus outbreaks caused by the 
emerging GII.17 virus. Norovirus strain typing ideally should include ORF1 
sequences and the variable VP1 ‘D’ region as well as metadata on the host, 
like clinical symptoms, immune status and blood group. This will allow us to 
better study and monitor the genetic disposition, pathogenesis, evolution and 
epidemiology of this newly emerged virus.
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Abstract 
Noroviruses are a common aetiology of acute gastroenteritis worldwide. 
Development of vaccines requires detailed understanding of global genetic 
diversity of noroviruses. This study describes trends in epidemiology and 
diversity based on global NoroNet surveillance data, and gives a future 
perspective on the global surveillance needs in light of these developments. The 
study analysed n=16635 norovirus sequences with associated epidemiological 
metadata, shared between 2005 and 2016 through NoroNet by partners from 
Europe, Asia, Oceania, and Africa. Sequences and epidemiological data were 
obtained from samples collected for outbreak investigations and diagnosis of 
sporadic gastroenteritis cases by clinical-, public health-, and food microbiology 
laboratories. During the study period, 26 different norovirus capsid genotypes 
circulated and 22 different recombinant genomes were found. The previously 
observed 2-3-year periodicity of emergence of genogroup II genotype 4 (GII.4) 
drift variants was not observed since 2012. Instead, the GII.4 Sydney capsid 
seems to persist through recombination, and we report a novel recombinant 
of GII.P16-GII.4 Sydney 2012 variant in Asia and Europe. The novel GII.
P17-GII.17, first reported in Asia in 2014, has circulated widely in Europe. GII.4 
viruses were more common in outbreaks in healthcare settings compared to 
other genotypes. Continuous changes in the global norovirus genetic diversity 
highlight the need for sustained global norovirus surveillance, including 
assessment of possible immune escape and evolution by recombination to 
provide a full overview of norovirus epidemiology for future vaccine policy 
decisions.
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Research in context
Evidence before this study
We searched Pubmed for articles published before 9th of July 2017 using 
keywords (worldwide OR global) AND norovirus AND genetic AND diversity 
in the title or abstract, and found 109 original research articles. The majority 
of studies reported on norovirus genetic diversity in a limited geographic area, 
timeframe, or focused on a single genotype. None of the studies presented 
long-term global norovirus diversity trends combined with epidemiological 
metadata, except one study focusing on the global norovirus diversity among 
oyster outbreaks.
Added value of this study
This study reports long-term global trends in norovirus genetic diversity 
combined with epidemiological metadata, obtained from reports from 19 
countries across four continents/regions shared through a jointly owned 
database. It shows that multiple norovirus genotypes are co-circulating 
simultaneously with continuous and rapid changes in the norovirus genetic 
diversity worldwide, and with substantial regional differences, possibly reflecting 
differences in epidemiology, susceptibility, or both. We show differences in 
the preferred transmission route, preferred outbreak setting, and seasonal 
variation between norovirus genotypes. Finally, we discuss gaps in the norovirus 
surveillance and give recommendation for improvements to fulfil surveillance 
needs in light of vaccine development and other future interventions.
Implications of all the available evidence
Norovirus candidate vaccines are currently tested in clinical trials. This 
study shows that a future norovirus vaccine needs to induce broad protective 
immunity, or would need to be updated on a regular basis due to continuous 
and rapid changes in the norovirus genetic diversity. This study highlights the 
need for a global norovirus surveillance system using optimized sequencing 
protocols to monitor possible immune escape and evolution by recombination to 
provide data for vaccine updates. Future studies need to address the underlying 
factors for preferences in transmission routes, preferences in outbreak setting, 
and differences in seasonality among noroviruses. 
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Background
Acute gastroenteritis is the second greatest burden of all infectious diseases 
and norovirus is responsible for almost one fifth of all cases worldwide[1]. For 
healthy individuals, norovirus illness is typically self-limiting and of short 
duration, but risk groups like young children, elderly, and immunocompromised 
patients can suffer from prolonged symptoms[2]. In order to better understand 
the epidemiology and impact of norovirus and to identify (international) 
outbreaks, surveillance networks have been set up in some countries in the 
last two decades. These efforts have been challenging as norovirus surveillance 
is not mandatory in many countries, and if available does not always include 
genetic data. Despite these challenges, collaborative studies have identified 
international food-borne outbreaks, and substantially increased our knowledge 
on the norovirus diversity and antigenic evolution with the voluntary adoption 
of sequence-based typing[3, 4]. The genus Norovirus is highly diverse and divided 
in seven genogroups (G) of which GI, GII, and GIV have been found among 
humans. Genogroups are further subdivided in more than 40 genotypes[5]. 
The epidemiology and human health impact are strongly shaped by norovirus 
evolution through recombination or accumulation of mutations, known as 
genetic drift[6]. To capture this diversity, norovirus nomenclature is based on 
two parameters describing the genetic lineages of the gene encoding the viral 
polymerase (ORF1) and the capsid protein (ORF2). Polymerase genotypes are 
distinguished from capsid genotypes by a P in their name (e.g. GII.P4). This 
dual typing approach allows for tracking of noroviruses, including recombinant 
forms[7]. In 2002, an informal international data sharing network was established 
to study noroviruses and their diversity in relation to human health impact[8]. 
The work from NoroNet has contributed to the understanding that noroviruses 
from different genetic lineages may behave differently. Genogroup II genotype 
4 (GII.4) has been the predominant strain globally and responsible for approx-
imately 70% of outbreaks since the start of NoroNet[9-11]. The antigenicity of 
the capsid surface alters in a stepwise manner by selection of variants under 
the pressure of population immunity – a process called epochal evolution[3]. In 
addition, frequent exchanging of genes (recombination) results in emergence 
of novel noroviruses. There is currently no licensed norovirus vaccine on the 
market, but potential candidates have been tested in phase I and II clinical 
trials[12, 13]. Vaccine design is complicated by the large antigenic variation within 
the genus, and is currently targeting most commonly found genotypes. In 
view of the above, most likely, a future vaccine would need to be updated on a 
regular basis given the flexibility of norovirus to escape natural infection-derived 
population immunity, hence requiring improved coverage of surveillance[14]. We 
analysed whether and how data obtained via the NoroNet surveillance network 
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can be used to address the following outstanding questions regarding norovirus 
molecular epidemiology: 
1.  What are the trends in genomic diversity, recombination, and norovirus 
reporting? 
2.  Is there evidence for differences by genogroup / genotype in region, setting, 
and mode of transmission?
3.  Where do new variants of norovirus emerge and can emerging variants be 
predicted from globally linked surveillance data? 
Methods
NoroNet surveillance network
NoroNet links clinical-, public health-, and food microbiology laboratories 
willing to share norovirus molecular and epidemiological data on outbreaks 
and sporadic cases, and has been in existence since the mid-1990s[8, 10, 15]. The 
network started as EU funded network in 1999, continuing since 2002 as global 
NoroNet[8]. A jointly owned web-based database with online analysis tools was 
developed in which participants share and compare their data. Participation is 
on a give and take basis and partners have signed a code of conduct on uses 
of the data, after which they are granted full access to the data. Partners are 
expected to contribute to joint reports, and the joint database has been used for 
in depth studies following approval of partners. 
Samples and study area
Specimens were obtained for the purpose of outbreak investigations and 
diagnosis of sporadic gastroenteritis cases. All RT-PCR positive cases confirmed 
by sequencing can be shared via NoroNet. Data from partners with less than 
50 submitted sequences during the study period were excluded. Based on these 
criteria, the study included norovirus sequences obtained from samples collected 
in 19 countries: Austria, Belgium, China, Denmark, Finland, France, Germany, 
Hungary, Ireland, Italy, Japan, the Netherlands, New Zealand, Russia, Slovenia, 
South Africa, Spain, Sweden, and the United Kingdom. Less than 50 entries had 
been obtained from partners in Australia, Chile and Norway. 
Data analysis
All entries submitted from January 1st 2005 to November 17th 2016 were 
downloaded on November 18th 2016. Records from non-human origin, without 
sample date or with a sample date prior to 2005 were removed from the 
analysis. Norovirus sequences were genotyped by the online norovirus typing 
tool[16]. Sequences overlapping the ORF1/ORF2 for which ORF1 and ORF2 
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genotypes could be assigned were analysed separately. All available sequences 
in the NoroNet database, including those before 2005, were used for the 
analysis of first reports of emerging GII.4 variants. The Maximum likelihood 
trees were inferred with PhyML version 3.1, using the general time reversible 
(GTR) nucleotide substitution model with a proportion of invariant sites and a 
Γ  distribution of among-site rate variation[17].
Figure 1 Position of 16628 sequence reads on the norovirus genome. Each sequence represents a 
line in the figure. Boxes above the graph represent the norovirus open reading frames (ORFs) of ref-
erence GII.Pe-GII.4 Sydney 2012 (Genbank accession: JX459908). ORF1 encodes for a polyprotein 
that is post-translationally cleaved by the virus-encoded protease (Pro) into six non-structural pro-
teins (p48, NTPase, p22, VPg, Pro, and RNA-dependent RNA polymerase (RdRp)). ORF2 encodes 
for the major capsid protein (VP1) which consists of a shell (S) and protruding domains P1 and P2 
with antigenic epitopes A, D, and E. ORF3 encodes for the minor capsid protein VP2.
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Figure 2 Number of reported ORF1 sequences (n=11252) stratified per genotype group, genotype, 
and year (A) and number of reported ORF2 sequences (n=6423) stratified per genotype group, 
genotype, and year (B). Note that n=1047 sequences overlapping ORF1/ORF2 are counted for both 
ORF1 and ORF2. Figure continues on the next page.
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
GI.P1 4 (0,9) 0 (0) 2 (0,2) 0 (0) 0 (0) 1 (0,1) 2 (0,2) 0 (0) 4 (0,3) 3 (0,3) 6 (0,7) 1 (0,1)
GI.P2 3 (0,7) 13 (1,7) 5 (0,6) 3 (0,4) 0 (0) 3 (0,2) 3 (0,3) 5 (0,4) 2 (0,1) 17 (1,6) 10 (1,1) 17 (2,1)
GI.P3 9 (2,1) 7 (0,9) 17 (2,1) 18 (2,2) 16 (2,1) 4 (0,3) 7 (0,7) 10 (0,9) 34 (2,4) 39 (3,7) 51 (5,5) 7 (0,9)
GI.P4 9 (2,1) 7 (0,9) 5 (0,6) 5 (0,6) 33 (4,2) 32 (2,3) 21 (2,2) 14 (1,2) 40 (2,9) 4 (0,4) 10 (1,1) 12 (1,5)
GI.P5 2 (0,5) 1 (0,1) 0 (0) 0 (0) 1 (0,1) 0 (0) 0 (0) 0 (0) 6 (0,4) 4 (0,4) 7 (0,8) 3 (0,4)
GI.P6 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (0,3) 0 (0) 0 (0) 0 (0)
GI.P7 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 20 (1,5) 3 (0,3) 6 (0,5) 7 (0,5) 2 (0,2) 3 (0,3) 0 (0)
GI.P8 2 (0,5) 0 (0) 0 (0) 1 (0,1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 0 (0) 0 (0) 0 (0)
GI.P9 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 0 (0) 0 (0) 0 (0) 4 (0,3) 4 (0,4) 0 (0) 1 (0,1)
GI.Pa 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 2 (0,2) 2 (0,1) 0 (0) 0 (0) 0 (0)
GI.Pb 2 (0,5) 4 (0,5) 13 (1,6) 5 (0,6) 2 (0,3) 10 (0,7) 25 (2,6) 50 (4,3) 43 (3,1) 21 (2) 22 (2,4) 4 (0,5)
GI.Pd 3 (0,7) 2 (0,3) 1 (0,1) 0 (0) 1 (0,1) 0 (0) 1 (0,1) 1 (0,1) 3 (0,2) 9 (0,9) 0 (0) 4 (0,5)
GI.Pf 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (0,5) 1 (0,1) 2 (0,2) 5 (0,5) 1 (0,1)
GII.P2 15 (3,5) 10 (1,3) 9 (1,1) 8 (1) 11 (1,4) 23 (1,7) 11 (1,2) 17 (1,5) 39 (2,8) 35 (3,3) 34 (3,7) 43 (5,3)
GII.P3 1 (0,2) 2 (0,3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
GII.P4 269 (62,7) 649 (84,6) 603 (75,1) 639 (79,7) 603 (77,6) 1094 (79,6) 709 (74,2) 617 (53,4) 302 (21,5) 301 (28,7) 252 (27,3) 127 (15,5)
GII.P6 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 1 (0,1) 0 (0) 0 (0) 0 (0) 0 (0)
GII.P7 59 (13,8) 18 (2,3) 39 (4,9) 28 (3,5) 28 (3,6) 31 (2,3) 67 (7) 95 (8,2) 93 (6,6) 81 (7,7) 62 (6,7) 33 (4)
GII.P8 1 (0,2) 0 (0) 0 (0) 1 (0,1) 1 (0,1) 3 (0,2) 0 (0) 1 (0,1) 2 (0,1) 2 (0,2) 0 (0) 0 (0)
GII.P11 1 (0,2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
GII.P12 3 (0,7) 6 (0,8) 2 (0,2) 0 (0) 0 (0) 0 (0) 0 (0) 7 (0,6) 1 (0,1) 0 (0) 0 (0) 3 (0,4)
GII.P13 0 (0) 7 (0,9) 5 (0,6) 2 (0,2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
GII.P15 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 1 (0,1) 0 (0) 1 (0,1) 0 (0) 1 (0,1) 0 (0) 0 (0)
GII.P16 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 0 (0) 5 (0,5) 17 (1,5) 19 (1,4) 17 (1,6) 5 (0,5) 31 (3,8)
GII.P17 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 4 (0,4) 102 (11,1) 185 (22,6)
GII.P20 3 (0,7) 1 (0,1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 0 (0)
GII.P21 42 (9,8) 39 (5,1) 101 (12,6) 70 (8,7) 46 (5,9) 52 (3,8) 31 (3,2) 30 (2,6) 75 (5,3) 92 (8,8) 41 (4,4) 49 (6)
GII.P22 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 0 (0) 0 (0) 3 (0,3) 16 (1,1) 2 (0,2) 0 (0) 3 (0,4)
GII.Pc 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (0,3) 2 (0,2) 0 (0) 0 (0)
GII.Pe 0 (0) 1 (0,1) 0 (0) 12 (1,5) 24 (3,1) 7 (0,5) 7 (0,7) 225 (19,5) 686 (48,9) 384 (36,6) 291 (31,6) 281 (34,4)
GII.Pg 1 (0,2) 0 (0) 1 (0,1) 7 (0,9) 7 (0,9) 93 (6,8) 61 (6,4) 47 (4,1) 14 (1) 22 (2,1) 20 (2,2) 12 (1,5)
GII.Pm 0 (0) 0 (0) 0 (0) 3 (0,4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 429 (100) 767 (100) 803 (100) 802 (100) 777 (100) 1374 (100) 955 (100) 1155 (100) 1403 (100) 1048 (100) 922 (100) 817 (100)
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Results
Surveillance coverage
Sixteen countries (Austria, Belgium, Denmark, Finland, France, Germany, 
Hungary, Italy, the Netherlands, Spain, China, Japan, South Africa, Sweden, 
United Kingdom, Russia) submitted norovirus sequences in five or more 
successive years of which six countries submitted sequences during the entire 
study period (Finland, France, Germany, Hungary, Italy, and the Netherlands). 
The NoroNet surveillance network is well represented in Europe and has a 
smaller number of collaborators in Asia, Oceania, and Africa (Supplementary 
Table 1). 
Figure 2A (ORF1)
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 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
GI.1 3 (1,3) 6 (1) 0 (0) 0 (0) 1 (0,5) 4 (0,8) 3 (0,5) 0 (0) 5 (0,7) 2 (0,2) 6 (0,7) 7 (1,3)
GI.2 0 (0) 8 (1,3) 2 (0,9) 4 (1,9) 0 (0) 2 (0,4) 1 (0,2) 7 (0,8) 4 (0,5) 15 (1,7) 18 (2,2) 2 (0,4)
GI.3 11 (4,9) 4 (0,6) 4 (1,9) 11 (5,1) 5 (2,7) 6 (1,2) 8 (1,3) 22 (2,7) 42 (5,5) 36 (4) 40 (4,8) 11 (2)
GI.4 12 (5,4) 8 (1,3) 1 (0,5) 3 (1,4) 14 (7,4) 16 (3,2) 18 (3) 13 (1,6) 34 (4,5) 5 (0,6) 10 (1,2) 4 (0,7)
GI.5 2 (0,9) 2 (0,3) 0 (0) 1 (0,5) 1 (0,5) 1 (0,2) 0 (0) 0 (0) 7 (0,9) 3 (0,3) 5 (0,6) 5 (0,9)
GI.6 3 (1,3) 2 (0,3) 1 (0,5) 5 (2,3) 0 (0) 7 (1,4) 11 (1,8) 22 (2,7) 28 (3,7) 17 (1,9) 13 (1,6) 3 (0,6)
GI.7 0 (0) 1 (0,2) 0 (0) 1 (0,5) 0 (0) 8 (1,6) 2 (0,3) 9 (1,1) 4 (0,5) 1 (0,1) 4 (0,5) 0 (0)
GI.8 0 (0) 0 (0) 0 (0) 1 (0,5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
GI.9 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 5 (0,7) 3 (0,3) 0 (0) 0 (0)
GII.1 2 (0,9) 0 (0) 0 (0) 4 (1,9) 0 (0) 31 (6,3) 29 (4,8) 35 (4,2) 12 (1,6) 14 (1,6) 15 (1,8) 3 (0,6)
GII.2 6 (2,7) 7 (1,1) 7 (3,3) 7 (3,3) 9 (4,8) 6 (1,2) 15 (2,5) 11 (1,3) 30 (3,9) 29 (3,2) 34 (4,1) 22 (4,1)
GII.3 21 (9,4) 15 (2,4) 22 (10,3) 10 (4,7) 16 (8,5) 15 (3) 45 (7,4) 29 (3,5) 17 (2,2) 53 (5,9) 23 (2,8) 34 (6,3)
GII.4 107 (47,8) 493 (78,5) 163 (76,2) 151 (70,6) 118 (62,8) 327 (66,3) 402 (65,9) 559 (67,6) 479 (62,8) 628 (70,3) 500 (60,5) 257 (47,3)
GII.5 0 (0) 2 (0,3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (0,5) 13 (1,7) 3 (0,3) 0 (0) 0 (0)
GII.6 23 (10,3) 25 (4) 9 (4,2) 6 (2,8) 8 (4,3) 10 (2) 42 (6,9) 70 (8,5) 34 (4,5) 63 (7,1) 35 (4,2) 11 (2)
GII.7 28 (12,5) 43 (6,8) 0 (0) 1 (0,5) 2 (1,1) 4 (0,8) 18 (3) 26 (3,1) 28 (3,7) 3 (0,3) 7 (0,8) 8 (1,5)
GII.8 1 (0,4) 3 (0,5) 0 (0) 1 (0,5) 0 (0) 1 (0,2) 0 (0) 1 (0,1) 1 (0,1) 0 (0) 2 (0,2) 0 (0)
GII.10 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (0,2) 0 (0) 6 (0,7) 1 (0,1) 0 (0)
GII.12 0 (0) 1 (0,2) 3 (1,4) 1 (0,5) 9 (4,8) 37 (7,5) 4 (0,7) 6 (0,7) 1 (0,1) 2 (0,2) 8 (1) 2 (0,4)
GII.13 1 (0,4) 2 (0,3) 0 (0) 1 (0,5) 0 (0) 13 (2,6) 6 (1) 4 (0,5) 10 (1,3) 4 (0,4) 5 (0,6) 4 (0,7)
GII.14 2 (0,9) 0 (0) 1 (0,5) 5 (2,3) 3 (1,6) 1 (0,2) 2 (0,3) 2 (0,2) 7 (0,9) 1 (0,1) 6 (0,7) 6 (1,1)
GII.15 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0,1) 1 (0,1) 0 (0) 0 (0)
GII.16 1 (0,4) 2 (0,3) 0 (0) 0 (0) 0 (0) 1 (0,2) 1 (0,2) 1 (0,1) 0 (0) 0 (0) 0 (0) 0 (0)
GII.17 0 (0) 1 (0,2) 0 (0) 1 (0,5) 1 (0,5) 1 (0,2) 1 (0,2) 0 (0) 1 (0,1) 3 (0,3) 94 (11,4) 164 (30,2)
GII.20 1 (0,4) 3 (0,5) 0 (0) 0 (0) 1 (0,5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
GII.21 0 (0) 0 (0) 1 (0,5) 0 (0) 0 (0) 2 (0,4) 2 (0,3) 3 (0,4) 0 (0) 1 (0,1) 0 (0) 0 (0)
Total 224 (100) 628 (100) 214 (100) 214 (100) 188 (100) 493 (100) 610 (100) 827 (100) 763 (100) 893 (100) 826 (100) 543 (100)
Number of reported sequences, sequence length and genome position
A median of 870 (IQR 345) ORF1 sequences and a median of 577 (IQR 594) 
ORF2 sequences was reported per year. Sequence reads had an average length 
of 351 bases and the majority of sequences were located in the RNA-dependent 
RNA polymerase region of ORF1 or 5’ side of ORF2 (Figure 1). Only 2·7% 
of sequences covered the main antigenic sites located at the P2 domain of 
VP1. During the study period, 154 full VP1 sequences were reported including 
three full genome sequences (KC175323, KC631827, and KP998539). An 
increased number of reported ORF1 sequences was observed in years of or post 
introduction of new GII.4 variants (Den Haag 2006b in 2006, New Orleans 
2009 in 2009, and Sydney 2012 in 2012) which could be primarily attributed 
to GII.P4 and GII.Pe (Figure 2A). The apparent decline in number of reported 
sequences in 2016 is an artefact due to the selection of sequences until 
November 18th 2016 and a submission delay.
Figure 2B (ORF2)
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Figure 3 ORF1 GII.P4 variant trends per year (n=8083, top) and ORF2 GII.4 variant trends per year 
(n=4184, bottom). The relatively high proportion of viruses/sequences typed as “other” in the old-
est category of submissions is an artefact due to the typing tool that was used. This tool performs 
a phylogeny based assignment of norovirus sequences to genera, genotypes, and variants. For 
correct assignment of variants, the reference sequences need to be periodically updated, when a 
new variants arise. By focusing on correct assignment of recent sequences, older strains may then 
be labelled as “unknown” with the current version of the typing tool.
Norovirus diversity at the genotype level
The number of reported sequences and GI versus GII ratio per country was 
analysed to get a better understanding of the genogroup coverage and diversity 
(Supplementary Table 1). Overall, 1372 of 16635 (8·2%) sequences belonged 
to norovirus GI, 15256 of 16635 (91·7%) sequences belonged to GII, and 7 of 
16635 (0·0%) sequences belonged to GIV.1. Austria reported the lowest GI 
proportion (3·2%) and Sweden the highest (22·3%) among European countries, 
while countries in Asia and South Africa only reported GII strains. Trends per 
genotype per year for GI and GII are shown in Figures 2A and 2B. The most 
consistently and commonly detected genotype was GII.P4 with 6125 of 11252 
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(54·8%) ORF1 sequences and 4184 of 6423 (65·1%) ORF2 sequences listed 
as GII.4 by the phylogeny based typing tool. The remaining ~40% is a diverse 
mixture of 31 ORF1 and 25 ORF2 genotypes with some genotypes only detected 
incidentally, while other genotypes were detected more often in some years. 
Emergence of novel GII.17 genotype
NoroNet detected a sharp increase in the number of GII.P17 and GII.17 strains 
in 2015 – 2016 compared to previous years (Figure 2A and 2B). GII.P17 and / 
or GII.17 were widely detected among European countries (Belgium, Finland, 
France, Germany, Hungary, Italy, the Netherlands, Russia, and Slovenia) in 2015 
– 2016, but not in all (Ireland, Spain, and United Kingdom) (Supplementary 
Table 2A and Supplementary Table 2B). The GII.P17 and GII.17 proportion of 
total number of sequences per country showed large variation among European 
countries (range 4·2 - 53·9% and 5·3 - 44·5%, respectively). GII.P17 and GII.17 
were co-circulating with GII.P4, GII.Pe, and GII.4 strains in Europe, and were 
only more prevalent than GII.P4, GII.Pe, or GII.4 in France (ORF1) and Russia 
(ORF1 and ORF2). China and Japan submitted in total n=10 ORF1 and n=73 
ORF2 sequences to NoroNet in 2015 - 2016, and China reported n=1 GII.17 
strain. 
Trends in GII.4 variants
The NoroNet GII.4 variant distribution time trends are shown in Figure 3. In 
2006, GII.4 Hunter 2004 was replaced by GII.4 Den Haag 2006b, succeeded 
by GII.4 New Orleans 2009 and GII.4 Sydney 2012 in the Northern hemisphere 
winter seasons of 2009/2010 and 2012/2013, respectively. The GII.4 Sydney 
ORF2 variant circulated as recombinant with GII.Pe or GII.P4 New Orleans 
2009 since it emerged in 2012, and has not (yet) developed a new ORF1 variant. 
The GII.4 New Orleans 2009 ORF2 variant almost disappeared as of 2013, 
while the corresponding GII.P4 New Orleans ORF1 variant was still widely 
detected due to recombination with the GII.4 Sydney 2012 ORF2 variant. The 
GII.4 variant group ‘other’ represents variants that were only detected with 
limited geographic distribution and at low level incidence or sequences that 
could not be typed to the variant level by the norovirus genotyping tool i.e. due 
to a short sequence length. Variants that were detected infrequently during 
the study period are: Camberwell 1994, Farmington Hills 2002, Asia 2003, 
Kaiso 2003, Yerseke 2006a, Apeldoorn 2007, and Osaka 2007. A novel GII.
P16-GII.4 Sydney 2012 recombinant was detected in 2014 (n=2) (Germany and 
the Netherlands), not detected in 2015, and detected in Japan, China, and the 
Netherlands (n=13) in 2016 (see paragraph recombination for more information 
on the novel GII.P16-GII.4 Sydney 2012 recombinant). 
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Figure 4 Norovirus seasonality patterns 
in Europe (n=13935) (A), Africa (n=195) 
(B), Asia (n=262) (C), and Oceania 
(n=806) (D), stratified per genotype 
group. Records without sample month 
were removed for this analysis. 
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Figure 5 Norovirus transmission route (n=8772) (A) and suspected outbreak setting (n=6446) (B), 
stratified per genotype group. Records without known transmission route or suspected outbreak 
setting were removed. Outbreaks with suspected foodborne origin and subsequent person-to- 
person transmission were recoded as foodborne.
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Origin of novel GII.4 drift variants
To assess when and where novel drift variants originate, we assessed the 
sampling date and country of origin of the first reported sequence of global 
drift variants (Supplementary Table 3). All assessed variants, except Hunter 
2004, were detected 2-5 years before the global predominance of the particular 
strain, which may indicate that new drift variants were present at low levels in 
the population before their actual global emergence. Hunter 2004 was firstly 
detected in the Netherlands in the year of emergence 2004. 
Recombination
To assess the influence of ORF1/ORF2 recombination on the norovirus diversity, 
we selected all sequences (n=1047) that were overlapping the ORF1/ORF2 
junction and for which both ORF1 and ORF2 sides could be genotyped by the 
norovirus genotyping tool. 477 of 1047 (45·6%) sequences were assigned as a 
recombinant strain (Supplementary Table 4). No between genogroup recombi-
nation was observed. Remarkably, some polymerase types are more prone to 
recombine than others. Recombination within GII was most common: 457 
recombinant sequences belong to GII of which GII.Pe–GII.4, GII.P21–GII.3, 
and GII.P7–GII.P6 are the most commonly detected recombinants. ORF2 
GII.4 has been detected in combination with GII.P12, GII.P16, and GII.Pe. The 
GII.P12 recombinant was detected in 2005 – 2006 in combination with GII.4 
Asia 2003. GII.P16 and GII.Pe are both only found in combination with GII.4 
Sydney 2012 between 2014 and 2016 (data not shown). GII.P16 was found in 
combination with five different VP1 genotypes: GII.3, GII.4, GII.10, GII.12, and 
GII.13 which each form a separate clade in a maximum likelihood tree inferred 
from partial GII.P16 sequences (Supplementary Figure 1). Three variants of GII.4 
Sydney are currently co-circulating, all resulting from recombination: GII.P4 
Orleans 2009-GII.4 Sydney 2012, GII.Pe-GII.4 Sydney 2012 and GII.P16-GII.4 
Sydney 2012. The antigenic regions in the capsid do not contain any amino acid 
changes compared to previously circulating GII.4 Sydney strains, although the 
VP1 sequences of GII.P16-GII.4 Sydney 2012 cluster separately from other GII.
Pe-GII.4 Sydney strains (Supplementary Table 5 and Supplementary Figure 2). 
Differences by season, region, setting, and mode of transmission
The European norovirus season coincides with the Northern Hemisphere 
winter season (Figure 4A). GII.Pe/GII.P4-GII.4 sequences show the clearest 
winter seasonality patterns while GI and GII non GII.Pe/GII.P4-GII.4 strains 
are more continuously present throughout the year, but never exceed the 
number of GII.Pe/GII.P4-GII.4 sequences. The rate of norovirus submissions 
in Africa (all reported by South Africa) shows an elevation in the months 
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September – November which coincides with the Southern Hemisphere spring 
season (Figure 4B). Asia (reported by China and Japan) shows an elevation of 
the norovirus incidence in the Northern Hemisphere winter season with the 
peak in November, two months earlier compared to Europe (Figure 4C). Oceania 
(reported by New Zealand) shows highest incidence in October and November 
(spring) (Figure 4D). 
The suspected mode of transmission was reported for n=6446 entries: 77·4% 
person-to-person transmission (n=4990), 19·9% foodborne transmission 
(n=1280), 2·1% waterborne transmission, and 0·7% other transmission mode 
(n=133, n=43, respectively) (Figure 5A). GII.4 is relatively more often transmitted 
via person-to-person compared to other genotypes. 
The setting of the norovirus outbreak was reported for n=8772 entries: 29·7% 
hospital setting (n=2603), 36·0% residential institution (n=3154), 9·3% hotel, 
restaurant or caterer (n=819), 11·8% day care or school (n=1039), 13·2% other 
(n=1157) (Figure 5B). The majority of sequences were derived from samples 
obtained in health care - or residential institutions. GII.4 was relatively more 
often detected in healthcare settings (hospitals and residential institutions) 
compared to non-GII.4 genotypes.
Discussion
Despite differences in norovirus surveillance among countries and a lack of it in 
many others, the current NoroNet system is able to observe global trends and 
major shifts in the genetic composition of the virus population at the level of 
genotype and variant, as was shown by this study and by others[6, 10, 18, 19]. 
The first question addressed in this study is about the trends in norovirus 
genomic diversity, recombination, and norovirus reporting. During the study 
period, we observed circulation of at least 26 ORF2 genotypes when looking at 
diversity of the capsid gene. The viral capsid contains epitopes that are targeted 
by protective antibody responses, and understanding this diversity is important 
for evaluation of candidate vaccines[20]. It was previously noted that increased 
notification reflect true increases in disease trends[18, 21]. Therefore, the observed 
increase in reported sequences post emergence of new GII.4 variants is probably 
related to an increase in norovirus activity. GII.4 Sydney 2012 is the predomi-
nantly detected variant worldwide since 2012 and, given the replacement cycle 
of two to three years shown for previous variants, a new antigenic variant has 
been anticipated for some years. This trend in antigenic evolution, however, 
was not observed in the period described here. Instead, viruses with GII.4 
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Sydney capsids, have evolved by recombination, suggesting that recombination 
somehow favours virus maintenance in the population. For GII.4, recombi-
nation has previously only been with the closely related sequence types GII.
Pe and GII.P12, which are both suggested to be derived from an ancestor of 
GII.P4[22]. The drivers for emergence of recombinant genomes in a population 
previously exposed to the same capsid sequences remains to be understood. 
The novel recombinant GII.P16-GII.4 Sydney 2012 may have increased fitness 
due to changes in the RNA dependent RNA polymerase (RdRp) that alter the 
polymerase fidelity and interaction with VP1, leading to differences in replication 
and/or transmission efficiency[23-26]. 
In addition to the globally prevalent GII.4 viruses, recent studies from Asia 
reported a major shift in genotype composition from the predominant GII.4 
to the novel GII.P17-GII.17 norovirus strain (GII.17 Kawasaki 2014) late 2014 
and onwards[19, 27]. The number of detected GII.P17-GII.17 strains among 
Asian countries within our network was limited and likely caused by a filtered 
submission of the respective countries. The GII.P17-GII.17 strain was widely 
detected among most European countries in 2015 and 2016 and showed 
substantial differences in prevalence among countries. This strain has not (yet) 
fully replaced GII.4 strains. 
The great genetic diversity of noroviruses is typically not considered in epidemi-
ological or clinical studies, but may translate to differences in the epidemiology. 
Therefore, we compared distribution of reported modes of transmission 
and settings for the reported outbreaks by genotype (question 2). The most 
commonly reported transmission mode for the GII.4 outbreaks reported 
to NoroNet was person-to-person transmission and the most commonly 
reported setting was residential institution[10]. Underlying driving factors for 
these differences compared with other genotypes are unknown. We observed 
substantial regional variation in the norovirus genotype distribution possibly 
reflecting differences in epidemiology, susceptibility of the population, or both.
Norovirus surveillance is done on a voluntary basis since funding for the 
network is unavailable. This is reflected by unstable reporting behaviour of many 
countries and a potential bias in this study. A limitation of the NoroNet network 
is that unstandardized convenience sampling and irregular submission affects 
the ability of the network to robustly identify the effect of introduction of new 
genotypes and variants on the norovirus impact and severity. Another limitation 
of the study are the gaps on the surveillance map with missing or limited 
data from most countries in Africa, Middle East, North – and South America, 
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Oceania, and Asia. The USA and Australia do have norovirus surveillance, but 
use separate databases to store and analyse their data. Future integration of 
surveillance databases could help to improve our understanding of the norovirus 
(molecular) epidemiology. 
A potential use of the NoroNet network is the identification of international 
outbreaks, which have been observed during periods of sustained funding[4, 
28]. The currently provided sequence data can be used to genotype a virus to 
the level of genotype and variant, but is less suitable for phylogenetic analysis 
for the purpose of international outbreak investigations due to the lack of 
standardisation of sequencing protocols. The use of next generation sequencing 
is explored to allow whole genome sequencing as a new standard to overcome 
this problem[29-31]. Most countries currently upload data to the NoroNet database 
batch wise, which leads to a submission delay and identification of international 
outbreaks potentially months after their occurrence. Countries would need to 
upload data on a weekly basis to be able to set effective public health measures 
(i.e. withdraw of a contaminated food product from the market). 
Norovirus vaccine candidates are currently in phase I and II trials and although 
vaccine cross-protection, efficacy, and effectiveness need to be evaluated, 
especially in vulnerable patient populations, it seems likely that a norovirus 
vaccine will be available in the near future. Such a vaccine will likely need to be 
updated on a regular basis due to escape of the virus from population immunity, 
especially by the predominant GII.4[32]. Essential data about the antigenic 
changes, especially those located in the P2 domain of the major capsid of the 
virus, can be obtained via a global surveillance system. As a minimum, a shared 
protocol for sequencing is needed, preferably including the ORF1 / ORF2 
overlap to genotype both the viral RNA-dependent RNA polymerase and VP1, 
and to detect recombinant strains. A protocol for sequencing this particular 
region has been described[33]. In addition to this protocol, a subset of specimens 
could be monitored for changes in the antigenic regions using a protocol 
spanning the P domain of VP1. Whole genome sequencing via next generation 
sequencing techniques could replace both protocols and potentially provide a 
better insight in the evolution of the virus, including the not well studied VP2. 
One of the major questions within the norovirus research field is whether we 
are capable of predicting emerging variants in the near future, the third and last 
question addressed in our study. All recent major drift variants were already 
circulating years before they became dominant as shown by this study and by 
others, suggesting early warning surveillance for variant emergence would be 
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possible[34]. If we assume that new variants develop in the human population and 
could emerge anywhere in the world, as shown by this study and by others, this 
would require a surveillance system with global coverage including large-scale 
genomics to capture both capsid diversity and recombination[35, 36]. A next step 
would be to predict antigenic properties from the genomic diversity, although 
this is likely to be challenging and requires development of phenotypic assays to 
assess antigenicity and immunity, similar to the model of the global influenza 
virus surveillance network. More research and new funding sources are needed 
to address these issues.
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Supplementary Table 1 Number of reported GI and GII sequences per continent/region and 
country
Continent Country GI (%) GII (%) Total
Europe Austria 6 (3,2) 180 (96,8) 186
Europe Belgium 41 (11,4) 319 (88,6) 360
Asia China 0 (0) 142 (100) 142
Europe Denmark 67 (10,4) 580 (89,6) 647
Europe Finland 96 (8,5) 1037 (91,5) 1133
Europe France 267 (8,2) 3004 (91,8) 3271
Europe Germany 183 (16,4) 932 (83,6) 1115
Europe Hungary 43 (5,2) 791 (94,8) 834
Europe Ireland 11 (7) 147 (93) 158
Europe Italy 23 (7,7) 276 (92,3) 299
Asia Japan 0 (0) 293 (100) 293
Europe Netherlands 327 (6) 5100 (94) 5427
Australia New Zealand 148 (18,4) 658 (81,6) 806
Europe Russia 23 (7,5) 283 (92,5) 306
Europe Slovenia 15 (6,7) 209 (93,3) 224
Africa South Africa 0 (0) 195 (100) 195
Europe Spain 16 (5,5) 274 (94,5) 290
Europe Sweden 69 (22,3) 241 (77,7) 310
Europe United Kingdom 37 (5,9) 595 (94,1) 632
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Supplementary Table 3 First detections of global GII.4 drift variants
GII.4 variant Year of 
emergence
First record 
ORF1
First ORF1 
country
first record 
ORF2
First ORF2 
country
Hunter 2004 2004 6-Apr-2004 The Netherlands 6-Apr-2004 The Netherlands
Den Haag 
2006b
2006 14-Feb-2002 Germany 30-Sep-2003 Japan
New Orleans 
2009
2009 12-Dec-2006 France 24-Apr-2009 South Africa
Sydney 2012 2012 - - Oct-2007 The Netherlands
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0.02
GII.P16 GII.3 13-03-2013 ITALY
GII.P16 GII.13 05-02-2014 NETHERLANDS
GII.P16 GII.12 31-10-2015 NETHERLANDS
GII.P16 GII.4 Sydney 2012 01-2016 JAPAN
GII.P16 GII.4 CNA 22-04-2016 NETHERLANDS
GII.P16 GII.4 Sydney 2012 02-09-2016 HONGKONG
GII.P16 GII.4 Sydney 2012 25-03-2016 HONGKONG
GII.P16 GII.4 CNA 25-07-2016 NETHERLANDS
GII.P16 GII.4 Sydney 2012 11-08-2014 GERMANY
GII.P16 GII.4 Sydney 2012 27-01-2016 HONGKONG
GII.P16 GII.12 15-01-2016 NETHERLANDS
GII.P16 GII.10 27-08-2014 NETHERLANDS
GII.P16 GII.4 Sydney 2012 17-11-2014 NETHERLANDS
GII.P16 GII.12 14-03-2015 NETHERLANDS
GII.P16 GII.4 Sydney 2012 05-08-2016 HONGKONG
GII.P16 GII.3 05-12-2012 ITALY
GII.P16 GII.12 23-11-2015 NETHERLANDS
GII.P16 GII.4 Sydney 2012 27-03-2016 HONGKONG
GII.P16 GII.13 10-12-2013 NETHERLANDS
GII.P16 GII.12 03-12-2015 NETHERLANDS
GII.P16 GII.10 27-08-2014 NETHERLANDS
GII.P16 GII.10 02-09-2014 NETHERLANDS
GII.P16 GII.13 05-02-2014 NETHERLANDS
GII.P16 02-09-2014 NETHERLANDS
GII.P16 GII.10 22-07-2014 NETHERLANDS
GII.P16 GII.4 CNA 25-07-2016 NETHERLANDS
GII.P16 GII.10 15-07-2014 NETHERLANDS
GII.P16 GII.4 Sydney 2012 04-04-2016 HONGKONG
GII.P16 GII.4 Sydney 2012 03-2016 JAPAN
GII.P16 14-01-2011 NETHERLANDS
GII.P16 GII.10 14-07-2014 NETHERLANDS
GII.P16 GII.4 Sydney 2012 04-09-2016 HONGKONG
GII.P16 29-09-2016 RUSSIANFEDERATION
GII.P16 GII.4 Sydney 2012 01-09-2016 HONGKONG
61
100
71
GII.4 Sydney 2012
GII.13
GII.12
GII.10
GII.3
Could Not Assign
ND
Supplementary Figure 1 Maximum likelihood tree for region B of ORF1 sequences displaying the 
genetic diversity of GII.P16 sequences that are found in combination with different VP1 sequences 
(used sequence length 289 nucleotides, n=34). GII.P16-GII.4 Sydney 2012 sequences are indicated 
in red.
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0.04
GII.4 Den Haag 2006b 18-12-2006 NETHERLANDS
GII.4 Den Haag 2006b 11-12-2006 NETHERLANDS 
GII.4 Den Haag 2006b 07-12-2006 NETHERLANDS
GII.4 Den Haag 2006b 12-05-2006 NETHERLANDS school
GII.4 Den Haag 2006b 05-12-2007 NETHERLANDS
GII.4 Den Haag 2006b 11-01-2008 NETHERLANDS
GII.4 Den Haag 2006b 10-2008 NETHERLANDS 
GII.4 Den Haag 2006b 12-02-2009 NETHERLANDS
GII.4 Den Haag 2006b 18-10-2007 NETHERLANDS
GII.4 Den Haag 2006b 06-10-2007 NETHERLANDS
GII.4 Den Haag 2006b 12-10-2007 NETHERLANDS
GII.4 Den Haag 2006b 30-03-2006 NETHERLANDS
GII.4 Den Haag 2006b 25-12-2008 NETHERLANDS
GII.4 Den Haag 2006b 10-2008 NETHERLANDS 
GII.4 Den Haag 2006b 04-12-2006 NETHERLANDS
GII.4 Den Haag 2006b 10-01-2008 NETHERLANDS
GII.4 Den Haag 2006b 08-01-2007 NETHERLANDS
GII.4 Den Haag 2006b 09-02-2009 NETHERLANDS
GII.4 Den Haag 2006b 11-11-2006 NETHERLANDS
GII.4 Den Haag 2006b 31-10-2006 NETHERLANDS
GII.4 Den Haag 2006b 03-01-2007 NETHERLANDS
GII.P16 GII.4 Sydney 2012 03-2016 JAPAN food 
GII.P16 GII.4 Sydney 2012 25-07-2016 NETHERLANDS
GII.4 Sydney 2012 02-07-2015 HONGKONG 
GII.4 Sydney 2012 13-11-2015 HONGKONG
GII.4 Sydney 2012 28-10-2014 HONGKONG 
GII.4 New Orleans 2009 05-06-2009 SOUTHAFRICA 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 05-02-2012 ITALY 
GII.4 Sydney 2012 18-01-2015 HONGKONG
GII.4 Sydney 2012 17-10-2015 HONGKONG 
GII.4 Sydney 2012 21-08-2015 HONGKONG 
GII.4 Sydney 2012 07-01-2015 HONGKONG
GII.4 Sydney 2012 01-12-2015 HONGKONG 
GII.4 Sydney 2012 13-06-2015 HONGKONG
GII.Pe GII.4 Sydney 2012 07-10-2014 HUNGARY
GII.P16 GII.4 Sydney 2012 27-01-2016 HONGKONG 
GII.Pe GII.4 Sydney 2012 07-10-2014 HUNGARY
GII.4 Sydney 2012 10-11-2014 HONGKONG
GII.4 New Orleans 2009 17-09-2010 SOUTHAFRICA 
GII.4 Sydney 2012 01-04-2015 HONGKONG 
GII.4 Sydney 2012 06-02-2015 HONGKONG 
GII.4 Couldnotassign 01-07-2010 SOUTHAFRICA 
GII.4 Yerseke 2006a 12-2006 NETHERLANDS 
GII.4 Yerseke 2006a 04-2008 NETHERLANDS 
GII.4 Sydney 2012 28-06-2015 HONGKONG 
GII.4 Sydney 2012 24-09-2014 HONGKONG
GII.4 Yerseke 2006a 18-10-2007 NETHERLANDS
GII.4 Sydney 2012 11-02-2014 HONGKONG 
GII.4 Sydney 2012 24-08-2015 HONGKONG
GII.4 Yerseke 2006a 04-2008 NETHERLANDS 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 10-11-2011 ITALY 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 01-10-2011 ITALY 
GII.4 Sydney 2012 23-08-2015 HONGKONG
GII.4 Sydney 2012 10-2007 NETHERLANDS
GII.4 Sydney 2012 22-12-2014 HONGKONG 
GII.P4 New Orleans 2009 GII.4 Sydney 2012 10-01-2013 ITALY 
GII.4 Sydney 2012 07-01-2015 HONGKONG 
GII.4 Sydney 2012 21-11-2015 HONGKONG 
GII.4 Sydney 2012 18-02-2014 HONGKONG
GII.P16 GII.4 Sydney 2012 05-08-2016 HONGKONG 
GII.4 Yerseke 2006a 08-11-2006 NETHERLANDS
GII.Pe GII.4 Sydney 2012 29-09-2014 HUNGARY
GII.4 Sydney 2012 30-10-2015 HONGKONG 
GII.4 Sydney 2012 25-02-2013 HONGKONG
GII.Pe GII.4 Sydney 2012 10-12-2012 HONGKONG 
GII.4 Sydney 2012 24-08-2015 HONGKONG 
GII.Pe GII.4 Sydney 2012 07-10-2014 HUNGARY
GII.4 Sydney 2012 03-08-2014 HONGKONG 
GII.P16 GII.4 Sydney 2012 01-09-2016 HONGKONG 
GII.Pe GII.4 Sydney 2012 26-09-2014 HUNGARY
GII.4 Yerseke 2006a 08-01-2008 NETHERLANDS
GII.4 New Orleans 2009 07-05-2009 SOUTHAFRICA 
GII.P16 GII.4 Sydney 2012 01-2016 JAPAN school
GII.4 Sydney 2012 02-03-2015 HONGKONG 
GII.4 New Orleans 2009 15-05-2009 SOUTHAFRICA 
GII.4 Sydney 2012 01-09-2015 HONGKONG
GII.4 Yerseke 2006a 30-01-2007 NETHERLANDS
GII.Pe GII.4 Sydney 2012 01-2012 JAPAN
GII.4 Sydney 2012 18-02-2015 HONGKONG 
GII.P16 GII.4 Sydney 2012 25-03-2016 HONGKONG 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 10-10-2011 ITALY 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 24-01-2011 ITALY 
GII.4 Yerseke 2006a 20-11-2006 NETHERLANDS
GII.4 New Orleans 2009 05-08-2009 SOUTHAFRICA 
GII.4 Sydney 2012 13-10-2015 HONGKONG 
GII.4 Sydney 2012 01-10-2015 HONGKONG 
GII.4 Sydney 2012 08-10-2012 HONGKONG
GII.4 Sydney 2012 14-04-2015 HONGKONG
GII.4 Sydney 2012 06-07-2010 SOUTHAFRICA 
GII.Pe GII.4 Sydney 2012 12-05-2014 HUNGARY
GII.4 New Orleans 2009 10-09-2009 SOUTHAFRICA 
GII.4 Sydney 2012 29-10-2014 HONGKONG
GII.4 Sydney 2012 08-01-2015 HONGKONG
GII.4 Sydney 2012 22-01-2015 HONGKONG 
GII.P16 GII.4 Sydney 2012 02-09-2016 HONGKONG 
GII.4 Sydney 2012 11-02-2014 HONGKONG 
GII.Pe GII.4 Sydney 2012 03-04-2014 HUNGARY
GII.4 Sydney 2012 31-10-2015 HONGKONG 
GII.4 Yerseke 2006a 08-01-2007 NETHERLANDS
GII.4 Sydney 2012 19-05-2010 SOUTHAFRICA 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 27-12-2011 ITALY 
GII.4 Sydney 2012 17-07-2015 HONGKONG 
GII.4 Sydney 2012 02-09-2015 HONGKONG
GII.Pe GII.4 Sydney 2012 15-08-2012 HONGKONG 
GII.4 Apeldoorn 2007 04-12-2007 NETHERLANDS
GII.P16 GII.4 Sydney 2012 27-03-2016 HONGKONG 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 07-2009 NETHERLANDS
GII.4 Hunter 2004 20-01-2006 NETHERLANDS
GII.4 Sydney 2012 16-10-2015 HONGKONG 
GII.4 Hunter 2004 12-02-2006 NETHERLANDS
GII.P16 GII.4 Sydney 2012 04-09-2016 HONGKONG 
GII.4 New Orleans 2009 08-04-2010 SOUTHAFRICA 
GII.4 Sydney 2012 13-11-2014 HONGKONG
GII.4 Sydney 2012 03-09-2015 HONGKONG 
GII.4 Sydney 2012 17-08-2015 HONGKONG
GII.4 Could not assign 03-09-2009 SOUTHAFRICA 
GII.4 Yerseke 2006a 02-12-2007 NETHERLANDS
GII.4 Sydney 2012 07-01-2015 HONGKONG
GII.P16 GII.4 Sydney 2012 04-04-2016 HONGKONG 
GII.4 Sydney 2012 01-11-2014 HONGKONG
GII.Pe GII.4 Sydney 2012 06-02-2014 HUNGARY
GII.4 Yerseke 2006a 07-03-2006 NETHERLANDS
GII.4 New Orleans 2009 22-09-2010 SOUTHAFRICA 
GII.4 Sydney 2012 01-01-2015 HONGKONG 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 21-02-2010 HUNGARY
GII.4 Yerseke 2006a 04-2008 NETHERLANDS 
GII.Pe GII.4 Sydney 2012 12-10-2014 HUNGARY
GII.4 Sydney 2012 28-02-2014 HONGKONG
GII.P16 GII.4 Sydney 2012 25-07-2016 NETHERLANDS
GII.4 Sydney 2012 18-04-2015 HONGKONG 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 06-06-2011 ITALY 
GII.4 Sydney 2012 14-04-2015 HONGKONG
GII.4 Yerseke 2006a 06-02-2006 NETHERLANDS
GII.4 Sydney 2012 12-09-2016 HONGKONG 
GII.4 Sydney 2012 31-12-2014 HONGKONG 
GII.4 Apeldoorn 2007 04-2008 NETHERLANDS 
GII.4 Osaka 2007 08-2006 NETHERLANDS 
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 30-01-2012 ITALY 
GII.4 Sydney 2012 18-12-2015 HONGKONG 
GII.4 Sydney 2012 28-10-2014 HONGKONG
GII.P4 New Orleans 2009 GII.4 New Orleans 2009 22-01-2013 ITALY 
GII.P16 GII.4 Sydney 2012 22-04-2016 NETHERLANDS
GII.Pe GII.4 Sydney 2012 10-10-2014 HUNGARY
GII.4 Sydney 2012 10-11-2014 HONGKONG
100
100
87
86
100
100
76
98
86
100
82
100
100
71
GII.4 Hunter 2004
GII.4 Yerseke 2006a
GII.4 Osaka 2007
GII.4 Den Haag 2006b
GII.4 Apeldoorn 2007
GII.4 New Orleans 2009
GII.4 Sydney 2012
GII.4 Could not assign
 
 
Supplementary Figure 2 Maximum likelihood tree inferred 
from all complete GII.4 VP1 sequences displaying the genetic 
diversity of GII.4 sequences that are detected in combination 
with different polymerase genotypes. GII.P16-GII.4 Sydney 
2012 sequences are indicated in red. 
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Abstract
Noroviruses are a major cause of acute gastroenteritis worldwide and are a 
genetically diverse group of viruses. Since 2002, an increasing number of 
norovirus outbreaks have been reported globally, but it is not clear whether 
this increase has been caused by a higher awareness or reflects emergence of 
new genogroup II genotype 4 (GII.4) variants. In this study the hypothesis is 
tested that the norovirus prevalence has increased post 2002 and related to the 
emergence of GII.4. Sera from children aged <5 years of three Dutch cross-sec-
tional population based cohorts collected in 1963, 1983, and 2006/2007 
(n=143, n=130, and n=376, respectively) were tested for specific serum IgG by 
protein array using antigens to GII.4 and a range of other antigens representing 
norovirus GI, GII, and GIV genotypes. The protein array was validated by 
paired sera of norovirus infected patients and supernatants of B-cell cultures 
with single epitope specificity. Evidence for norovirus infection was found to 
be common among Dutch children in each cohort, but the prevalence towards 
different genotypes changed over time. At the genogroup level, GI seroprev-
alence decreased significantly between 1963 and 2006/2007, while a significant 
increase of GII and particularly genotype GII.4 specific antibodies was detected 
in the 2006/2007 cohort. There were no children with solely GII.4 antibodies 
in the 1963 cohort. This study shows that the high GII.4 norovirus incidence in 
very young children is a recent phenomenon. These findings are of importance 
for vaccine development and trials that are currently focussing mostly on GII.4 
viruses.
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Introduction
Noroviruses belong to the family Caliciviridae and are a major cause of acute 
gastroenteritis in outbreaks and sporadic cases for all age groups worldwide[1]. 
Noroviruses are genetically highly diverse positive-stranded RNA viruses that 
can be divided into six genogroups (G) with a seventh genogroup recently 
proposed[2]. Viruses of GI, GII, and GIV are known to cause diarrheal disease in 
humans. The genogroups are further divided in approximately forty genotypes 
based on their phylogenetic clustering[3]. The lack of a robust cell culture system 
for norovirus has hampered the development of serological assays to study the 
population impact of individual norovirus genotypes. To be able to measure the 
immune response upon norovirus infection, ELISA assays based on virus-like 
particles (VLPs) produced through expression of the viral capsid protein 
(VP1) have been developed, but these assays cannot distinguish exposure to 
different genotypes due to high levels of cross-reactivity[4]. As a surrogate for 
virus neutralisation assays, assays have been developed to measure antibodies 
that block the binding of noroviruses to histo-blood group antigens[5]. These 
assays eliminate cross-reactivity observed for ELISA assays with VLPs, but 
are not suitable for population studies since they are difficult to standardise, 
 time- consuming, and need large quantities of serum and VLP’s. The VP1 
consists of a conserved shell (S) domain and the more variable P domain that 
contains all immunogenic sites. Upon expression of the norovirus P domain P 
particles will be formed, which are very stable and immunologically relevant, 
but which contain less cross-reactive epitopes owing to the absence of the 
conserved S-domain, as evidenced from comparative immunization studies in 
mice[6, 7].
Since the start of norovirus surveillance in the mid-1990s, GII.4 have been 
the predominant genotype across the globe, responsible for 62% of outbreaks 
and the majority of endemic illness[1, 8, 9]. The norovirus GII.4 epidemiology 
has similarities to that of influenza A viruses, with new antigenic variants 
emerging every 2-3 years that replace the previously established variant, and 
herd immunity as the main evolutionary driving force[10, 11]. Since the mid-1990s, 
six GII.4 variants with pandemic spread have been recognized: US95/96, 
Farmington Hills 2002, Hunter 2004, Den Haag 2006b, New Orleans 2009, 
and Sydney 2012[12]. Little is known about norovirus genetic diversity before the 
mid-1990s since molecular techniques were not yet available and historical 
faecal collections are exceedingly rare. To our knowledge only one study has 
looked at the GII.4 molecular epidemiology before 1996 and has found GII.4 
only in 9 of 48 (18.8%) faecal samples collected between 1974 and 1991[13]. 
Since the appearance of the GII.4 Farmington Hills 2002 variant, an increasing 
number of norovirus outbreaks have been reported compared to previous years, 
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Table 1 Antibody titres (95% confidence interval) in pre and post infection sera.
Patient Pre / 
post in-
fection
Days 
rela-
tive to 
day of 
onset
Infecting 
geno-
type
GI.1 GI.2 GI.6 GI.8 GII.3 GII.4 GII.9
A Pre -32 Unknown 
history
20 20 20 20 20 20 20
A Post 52 GII.4 Den 
Haag 
2006b
20 20 20 20 411 
(331-
491)
5120 909 
(710-
1107)
B Pre -3 Unknown 
history
20 20 316 
(281-
352)
20 20 20 20
B Post 46 GII.4 New 
Orleans 
2009
20 20 145 
(120-
171)
20 86 
(72-
101)
5120 554 
(495-
613)
C Pre -1 Unknown 
history
20 20 20 20 136 
(120-
151)
20 20
C Post 13 GII.3 20 20 20 20 2481 
(2058-
2904)
191 
(165-
217)
249 
(223-
275)
D Pre -4 Unknown 
history
125 
(93-
158)
87 
(81-
94)
100 
(90-
110)
20 20 250 
(222-
278)
63 
(56-
70)
D Post 46 GI.6 20 20 553 
(491-
615)
20 20 127 
(105-
149)
20
but it is not clear whether this increase has been caused by a higher awareness 
or is an effect of the advancement of the emergence of antigenic drift variants 
of GII.4, or other evolutionary effects leading to increased fitness of these 
viruses at population level[14, 15]. Therefore, we wanted to test the hypothesis 
that the emergence of predomiant GII.4 viruses have been driving the increased 
norovirus burden since 2002. Sera from children under the age of 5 years were 
selected from three cross-sectional population based serum cohorts collected 
in 1963, 1983, and 2006/2007 and tested with a novel multiplex protein array 
to detect antibody responses to individual norovirus genotypes. Sera of young 
children were chosen to measure the impact of exposure to noroviruses in the 
first years of life. The protein array was validated using polyclonal rabbit sera, 
pre- and post- sera of norovirus infected individuals, and supernatants of B-cell 
cultures with single epitope specificity. 
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Materials and methods
Antigens
Norovirus P particles were used as antigens since they antigenically resemble 
native virions and can be produced in E. coli expression systems at relatively low 
costs as described[30, 31]. Furthermore P particles only contain the highly variable 
protruding (P) domain of the viral capsid protein (VP1), lack the more conserved 
S domain, and therefore contain less cross-reactive epitopes, as evidenced from 
comparative immunization studies in mice[6]. A GIV.1 VLP produced in insect 
cells was added to include antigens from all human genogroups. Since GIV is 
genetically not closely related to other human genogroups we did not expect 
cross-reactivity between these VLP and the P particles representing genotypes 
of GI and GII. We selected antigens representing common and rare genotypes 
as detected by the Noronet sequence database (Supplemental Table S1) (http://
www.noronet.nl). 
Norovirus protein microarrays for multiplex serology 
Purified P particles and VLPs were diluted in protein array buffer (Maine 
Manufacturing, Sanford, Maine, USA) and protease inhibitor (BioVision, 
Mountain View, CA, USA), with final concentration of 1 mg/mL (determined by 
checkerboard titration, data not shown). Proteins were spotted in triplicate with 
two 333 pL spots onto 64-pad nitrocellulose coated slides (Oncyte avid, Grace 
bio-labs, Bend, OR, USA) using a non-contact Piezorray spotter (PerkinElmer, 
Waltham, MA, USA) as described[32]. Slides were incubated with Blotto blocking 
buffer (Thermo Fisher Scientific Inc., Rockford, MA, USA) to avoid non-specific 
nitrocellulose binding, and subsequently with serial 4-fold diluted human sera 
starting at a 1:40 dilution. Rabbit sera and B-cell supernatants were tested at a 
single dilution (1:20 for rabbit sera, 1:8 for B-cell supernatant pools, and 1:4 for 
individual cultures). After washing, slides were incubated with goat anti-human 
IgG or anti-rabbit IgG (Fc-fragment specific), conjugated with Alexa Fluor 647 
fluorescent dye (Jackson Immuno Research, West Grove, PA, USA). Bound dye 
was quantified using a ScanArray Gx Plus microarray scanner (PerkinElmer). 
Assay validation samples
Two rabbit polyclonal sera from animals immunized with recombinant norovirus 
GII.4 Den Haag 2006b or GIV VP1 protein (Immune Technology, New York, 
USA) were tested on the protein array to confirm that antigens remain intact 
on the platform and to test homologous versus heterologous antigen reactivity. 
Pre and post infection sera of RT-PCR confirmed norovirus patients were used 
for assay validation. These patients were infected with GII.4 Den Haag 2006b, 
GII.4 New Orleans 2009, GII.3, or GI.6 respectively (ages 5, 47, 17, and 12 y). 
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Use of the sera for assay validation was approved by the Erasmus MC medical 
ethical committee (MEC2013-082). Further validation of the array platform 
was performed by using sera (n = 40, storage at -20° C) and peripheral blood 
mononuclear cells (PBMCs) (storage at -135° C) obtained from two donors (10 
years) who were sampled for a study on the memory immunity to Bordetella 
pertussis (ISRCTN64117538).
Quality control
The intra and inter assay variation was monitored by testing a serial diluted 
positive control serum consisting of pooled human sera reacting with high 
norovirus titre to antigens belonging to genogroup I and II. Samples tested 
on slides with a positive control deviated more than one 2-fold dilution step 
from the geometric mean titre were rejected from analysis. For the intra assay 
variation the positive control serum was tested 16 times on a single slide and to 
determine the inter assay variation the control serum was tested 44 times on 
multiple slides within 13 weeks. The quality of the GIV VLP was tested with a 
rabbit control serum (data not shown).
B-cell supernatants with single epitope specificity
B-cell supernatants with single epitope specificity were used to test the 
specificity of the protein array platform. B-cells were isolated, stimulated, and 
cultured in a limiting dilution assay with a slightly adjusted protocol as described 
before[16]. Briefly, PBMC were isolated within 24 h after venepuncture and stored 
at -135° C upon further use. The EasySep™ Human CD19 positive selection 
kit and EasySep magnet (Stemcell technologies, Cologne, Germany) were used 
to isolate the B-cells from the PBMC population. Purified B-cells were counted 
and re-suspended in 96-wells round bottom tissue culture plates with each well 
containing 500, 1000, or 4000 B-cells. Gamma irradiated CD40L-expressing 
murine fibroblast L cells were added in a concentration of 500 cells / well and 
3 µg/ml CpG ODN2006 (Isogen Life Sciences, Utrecht, Netherlands), 10 ng/
ml interleukin 2 (IL-2) (Miltenyi Biotec, Leiden, Netherlands) and 10 ng/ml 
IL-10 (BD Pharmingen, San Diego, USA) was added to promote cell division 
and antibody secreting cell (ASC) outgrowth. After 5 days of incubation at 37° 
C culture medium was refreshed and cytokines were replaced by 10 ng/ml IL-2 
and 10 ng/ml IL-21(Invitrogen, Waltham, USA) to promote antibody production. 
Supernatants were harvested after 11-12 days, stored at -20° C, and in vitro IgG 
production was tested by total IgG ELISA (data not shown). Supernatants were 
subsequently tested against multiple antigens representing GI and GII genotypes 
on the protein array platform.
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Study samples 
A total of 649 serum samples from children <5 years of age collected in 1963, 
1983, and 2006/2007 were included in the study, respectively n = 143, n = 
130, and n = 376 (Table 3). Sera collected in 1963 and 1983 were obtained 
from a Dutch historical anonymous collection of serum samples, that had been 
collected for diagnostic purposes (not specifically for acute gastroenteritis), 
and stored at -20° C since then at Erasmus MC, Rotterdam[33]. Sera collected 
between February 2006 and June 2007 were obtained from a Dutch population 
based cross-sectional serosurvey[34]. The study was approved by the Medical 
Ethics Committee, Almere (ISRCTN 20164309). 
Data- and statistical analysis
Serum titres were computed by fitting a 4-parameter log-logistic curve to 12 
luminescence readouts (4 dilutions, each antigen tested in triplicate), using the 
point of inflection as titre as described[32]. A fixed minimum fluorescent signal 
of 3000 was chosen to reduce background reactivity and a fluorescent signal of 
65535 was used as fixed maximum readout. Titres below the minimum dilution 
were set to a value half of the reciprocal minimal dilution and titres above the 
highest dilution were set to a value of 2 times the highest reciprocal serum 
dilution. Data of B-cell supernatants is shown as fluorescent signal (RFU) with 
the background signal subtracted since the supernatants were tested at a single 
dilution. Data analyses and statistical analysis were performed using R version 
3.0.3. The chi-squared test for trend was performed to examine differences in 
seroprevalence rates between age groups and cohorts. A p-value ≤ 0.05 was 
considered to be significant. The Spearman correlation coefficient was used 
to assess potential cross-reactivity patterns between antibody titres detected 
against multiple norovirus genotypes.
Results
Array specificity
A novel multiplex norovirus P particle protein array was developed to be able to 
measure norovirus genotype specific antibodies. First, the specificity of the newly 
developed array was confirmed using polyclonal sera of two rabbits immunized 
with VP1 protein from GII.4 and GIV, respectively. Both the GII.4 and GIV 
rabbit sera reacted with high signal with the homologous antigen without 
significant cross-reaction with the heterologous antigens (data not shown). 
Next, we tested pre and post infection sera of four norovirus RT-PCR confirmed 
patients infected with GII.4 Den Haag 2006b, GII.4 New Orleans 2009, GII.3, 
and GI.6 respectively (Table 1, Supplemental Figure S1). All patients showed a 
more than fourfold increase to the homologous antigen showing that P particles 
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in the array platform remain intact and are recognized by norovirus antibodies 
from patients. The pre infection sera of three patients (Table 1 patient B, C, 
and D) already showed reactivity, which was most likely caused by previous 
infections as expected since noroviruses are one of the most common infections 
during childhood. Antibody responses in the three GII infected patients (Table 1 
patient A, B, and C) were exclusively observed for GII antigens, particularly the 
homologous antigen, with low levels of cross-reactivity or boosting of previous 
infections with heterologous GII antigens. The serum sample of the GI.6 
infected patient (Table 1 patient D) showed a specific GI.6 reaction and did not 
bind to the heterologous GI and GII antigens.
Quality control
Using a positive control serum, consisting of pooled human sera, we determined 
that the average intra assay coefficient of variation (CV) for antibodies to 
individual P particle antigens was 9.0% (range 6.2-13.7%) and average CV inter 
Figure 1 Multiple scatterplot log transformed titres of children <5 y (n=649) to determine potential 
cross-reactive patterns among P particle antigens on the protein array platform. In the top right 
triangle Spearman correlation coefficients are plotted between each antigen pair, with significant 
numbers being highlighted by enlargement.
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assay variation 25.7% (range 16.9-36.0%). The VLP GIV was not included in 
this analysis since the human control serum was not reactive to this antigen. 
The potential degradation of antibodies over time was monitored by comparing 
the magnitude of titres among cohorts. High antibody titres against individual 
antigens were observed in all three cohorts indicating that the serum antibodies 
were not degraded (Supplemental Figure S2).
Potential cross-reactivity of antibodies towards the antigens on the array
Sera of children below 5 years of age (n=649) were assessed for potential 
cross-reactivity patterns by the Spearman correlation coefficient and plotting of 
log transformed titres between each possible antigen pair (Figure 1). Antibodies 
directed to antigens belonging to different genogroups typically did not show 
significant cross-reactivity in this age group, with a low correlation coefficient 
Table 2 B-cell supernatant profiles of two donors with a broadly reacting serum profile
Donor Cells GI.1 GI.2 GI.6 GI.8 GII.3 GII.4 GII.9
Pool 1-12 1 8000 - - - - - - -
Pool 13 1 8000 - - - - + - -
Pool 14 1 8000 - - - - +++ - -
Pool 1-7 2 4000 - - - - - - -
Pool 8 2 4000 - - - - - ++ -
Pool 9 2 4000 - + - + - - -
Pool 10 2 4000 - + - - - - -
Pool 11 2 4000 - - + - - - -
Pool 12 2 4000 +++ +++ +++ ++ - - -
Pool 12 
Culture 1-7
2 500 - - - - - - -
Pool 12 
Culture 8
2 500 +++ +++ +++ ++ - - -
Pool 13 2 4000 - +++ ++ - - - -
Pool 13 
Culture 1-7
2 500 - - - - - - -
Pool 13 
Culture 8
2 500 - +++ + - - - -
Pool 14 2 4000 - - - - - +++ -
Pool 15 2 4000 - + - - ++ - -
Pool 16 2 4000 ++ ++ ++ ++ - - -
Symbols -, +, ++, +++ represent respectively a fluorescent signal of 0 – 500, 501 – 5000, 5001 – 30000, >30000
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Table 3 Age stratified number of sera tested and percentage of sera with reactivity to any norovirus 
antigen.
Age group 1963 1983 2006/2007
 
n sera 
tested
% sera 
norovirus 
positive
 
n sera 
tested
% sera 
norovirus 
positive
n sera 
tested
% sera 
norovirus 
positive
<1 25 72.0 20 70.0 110 42.7
1-<2 32 50.0 23 56.5 57 64.9
2-<3 25 72.0 34 67.6 74 63.5
3-<4 27 66.7 24 79.2 75 85.3
4-<5 34 85.3 29 75.9 60 85.0
Total 143 69.2 130 70.0 376 65.4
GI GII GIV
0
10
20
30
40
50
60
70
80
90
NoV genogroup
1963
1983
2006/2007
**** *******
<1 1 2 3 4
0
10
20
30
40
50
60
70
80
90
Age ( years)
GII 1963
GII 1983
GII 2006/2007
*** ***
<1 1 2 3 4
0
10
20
30
40
50
60
70
80
90
Age ( years)
GIV 1963
GIV 1983
GIV 2006/2007
* ** ******
(a)
(c) (d)
(b)
<1 1 2 3 4
0
10
20
30
40
50
60
70
80
90
Age (years)
GI 1963
GI 1983
GI 2006/2007
**** *
Se
ro
pr
ev
al
en
ce
 (%
)
Se
ro
pr
ev
al
en
ce
 (%
)
Se
ro
pr
ev
al
en
ce
 (%
)
Se
ro
pr
ev
al
en
ce
 (%
)
Figure 2 Comparison of norovirus seroprevalence (n=649) stratified to cohort and genogroup (A). 
Age-related seroprevalence (n = 649) stratified to cohort for norovirus genogroup I (B), genogroup 
II (C), and genogroup IV (D). Error bars indicate binomial proportion confidence intervals (Wilson 
score interval). Brackets above bars show significance level as determined by chi-squared test for 
trend. No bracket = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, and **** = P ≤ 0.0001.
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ranging from 0.01- 0.27. Within a genogroup, some cross-genotype antibody 
reactivity was observed with correlation coefficients for heterotypic antibody 
reactivity ranging between 0.52- 0.67. This pattern was not consistent among 
sera indicating that cross-reactive patterns are complex, reflecting large 
individual variability rather than a primary technical cause.
B-cell supernatants with single epitope specificity
The observation that the sera of some of the young children were reactive to 
multiple antigens raised the question whether these children were already 
infected with multiple norovirus genotypes or contain cross-reactive antibodies, 
or both. Paired sera of forty children obtained at nine and ten years of age 
were screened on the protein array for the presence of broadly reacting serum 
antibody profiles. Two donors with a broad serum profile were selected and 
B-cells of these donors were polyclonally stimulated to become antibody 
secreting cells (ASC). Limiting dilution was carried out to create multiple 
cultures with single epitope specificity. B-cell supernatants were tested on the 
array to dissect the serological profiles of both donors, using limiting dilution to 
select for single B cell clones per well[16, 17]. Bulk cultures were first tested and all 
these cultures reacted with one or multiple antigens, confirming the serological 
reactivity observed in the sera of these children. For donor 1 only 2 of 14 (14.3%) 
of pools containing 8000 cells each were positive and both positive clones had 
single genotype specificity to genotype GII.3 (Table 2). Donor 2 did not meet the 
clonal criteria as 9 of 16 (56%) pools showed positive reaction to one or multiple 
norovirus antigens.Some supernatants showed broad GI reactivity, suggesting 
either the presence of a broadly reactive epitope, or mixed B cell populations. 
Subsequent testing of individual supernatants pool 12 and 13 confirmed 
reactivity to multiple genotypes within GI as only 1 of 8 cultures harbour 
reactivity to norovirus antigens, indicating that these reactivities were caused by 
a broadly reactive epitope. However, in both donors, multiple clones with single 
genotype specificity were also obtained, with GII.3 only reactive supernatants 
in donor 1, and GI.6- and GII.4- specific supernatants in donor 2, showing that 
technically, the array can measure genotype specific human antibodies. 
Seroprevalence
Next the seroprevalence against different norovirus genotypes in children <5 
years (n=649) was determined. Based on a pilot experiment with sera of children 
<1 year of age a cut off for positive samples was set at titre 40 (data not shown). 
The overall norovirus IgG seroprevalence has not significantly changed over time 
with 69.2%, 70.0%, and 65.4% of sera positive for at least one genotype in 
respectively 1963, 1983, and 2006/2007 (Table 3, chi-squared test for trend, 
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Table 4 Genotype distribution within positive sera with single antigen response.
Cohort GI.1 GI.2 GI.6 GI.8 GII.3 GII.4 GII.9 GIV.1 Total
n / % n % n % n % n % n % n % n % n % n %
1963 2 6.3 10 31.3 5 15.6 2 6.3 1 3.1 0 0.0 4 12.5 8 25.0 32 100
1983 2 6.5 4 12.9 1 3.2 3 9.7 1 3.2 6 19.4 14 45.2 0 0.0 31 100
2006/
2007
3 3.2 16 17.0 0 0.0 1 1.1 9 9.6 55 58.5 6 6.4 4 4.3 94 100
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Figure 3 Comparison of norovirus seroprevalence (n=649) stratified to cohort and genotype (A). 
Age-related broadening of the norovirus immune response (n=649) (B). Comparison of norovirus 
seroprevalence in sera (n=157) with single response stratified to cohort and genotype (C). Error bars 
indicate binomial proportion confidence intervals (Wilson score interval). Brackets above bars show 
significance level as determined by chi-squared test for trend. No bracket = P > 0.05, * = P ≤ 0.05, 
** = P ≤ 0.01, *** = P ≤ 0.001, and **** = P ≤ 0.0001.
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p-value = 0.3307). In children below one year of age, seroprevalence was 
already at a high level in 1963 and 1983 (respectively 72.0% and 70.0%), likely 
reflecting maternal antibodies. In the 2006/2007 cohort the seroprevalence for 
this age category was significantly lower (42.7%). More than half of the children 
were already seropositive by the second year of life, increasing to 85.3, 75.9, 
and 85.0% at age 4 in 1963, 1983, and 2006/2007, respectively. Interestingly, 
however, substantial differences were observed when breaking the reactivity 
down to genogroups and genotypes. At the genogroup level, GI seroprevalence 
dropped over time while the prevalence of GII antibodies increased (Figure 
2A). GIV prevalence was much higher in the first cohort, with 30.8% in 1963 
compared to 3.1% and 8.2% in 1983 and 2006/2007. Stratified by age, the 
highest GI seroprevalence decrease was seen among children of age <1 year 
and 2 years, while the largest GII increase was seen among children of 1 and 
3 years (Figure 2B and 2C). Seroprevalence for GIV was significantly higher in 
all age years in 1963 compared to cohort 1983 and 2006/2007 (Figure 2D). All 
four tested GI genotypes showed a significant reduction in seroprevalence over 
time, while the increase in GII antibodies was primarily caused by an increased 
reactivity to GII.3 and GII.4 antigens (Figure 3A). The antigen with highest 
seroreactivity was GI.2 in 1963, GII.9 in 1983, and GII.4 in 2006/2007. 
Broadening of immune response by increasing age
The multiplex composition of the protein array platform enabled the 
simultaneous detection of norovirus antibodies to various genotypes and allowed 
to measure the age-related broadening of the norovirus immune response (Figure 
3B). Using a cut off of 40, sera were stratified in three groups: sera without 
reactivity to any norovirus antigen, sera with reactivity to a single antigen only, 
and sera with multiple reactivity. A clear age-related increase in sera with 
multiple responses was observed, while the proportion of sera with monospecific 
responses remained stable (p-value chi-squared test for trend among respectively 
multiple, monospecific, and non-responders: <0.0001, 0.6981, <0.0001). 
Monospecific responses
To eliminate false positives due to the presence of broadly reactive antibodies, 
157 sera from children with antibodies limited to a single antigen were analysed 
separately (Table 4, Figure 3C). Interestingly, GII.4 antibodies were not detected 
as unique profile in the 1963 cohort, whereas they constituted 19.4% of 
monospecific sera in 1983, and were predominant with 58.5% in 2006/2007 
indicating a dramatic increase of antibodies to GII.4 or a closely related genotype 
over time. Furthermore, among antigens tested, GI.2 was predominant in 1963 
and GII.9 was predominant in 1983.
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Discussion
In this cross-sectional population study the norovirus seroprevalence was 
investigated among children <5 years of age from which serum was collected in 
1963, 1983, or 2006/2007. The results show that norovirus has been a common 
and widespread infection among Dutch children, at least since 1963, with no 
indication of an increase in the overall seroprevalence. This confirms prior 
studies using ELISA or related assays based on recombinant VLPs in China, 
Finland, India, Japan, Korea, Spain and the United Kingdom, although quite 
some variation in seroprevalence rates were observed by geographic location and 
sample year, which may in part be due to a lack of assay standardization[18-22]. 
It has been hypothesized that the emergence of GII.4 has resulted in a large 
increase of norovirus outbreaks since 2002[14, 15], and therefore we assessed 
exposure to individual norovirus genotypes, using a novel protein array. The 
validation experiments showed that a person’s serological profile may contain 
a mixture of genotype-specific as well as broadly-reactive antibodies with cross 
genogroup reactivity, although clear discriminatory serological profiles were 
obtained when looking at post-infection sera. This pattern is in concordance 
with the higher correlations found between antibodies to antigens of the same 
genogroup compared to antigens from different genogroups. Based on these 
observations, we concluded that the study design allows conclusions based on 
antibody trends by genogroup and genotype, although for the latter the potential 
for cross-reactive antibodies needs to be considered when interpreting the 
results.
Our study shows that – despite similar overall seroprevalence – the exposure 
histories shifted drastically over the period studied, and that the seroprev-
alence of GII.4 has indeed significantly increased over the last decades, with 
concomitant reduction in exposure to GI and GIV noroviruses. In theory, the low 
GII.4 seroprevalence in the 1963 and 1983 cohort could be caused by mismatch 
between circulating GII.4 variants and the antigen used in our assay (GII.4 
US95/96 antigen). This is however unlikely, as sera from patients infected with 
recent GII.4 variants bound efficiently to the GII.4 US95/96 variant antigen. 
Therefore, we conclude that the most likely explanation for the observed shift in 
norovirus exposure is that it reflects true epidemiological changes. The absence 
of sera from the 1963 cohort that only reacted to GII.4 suggests that either GII4 
viruses were not circulating, or that exposure of this genotype occurred at an 
older age. 
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Based on these data alone, we cannot draw conclusions on the clinical impact 
of these shifts in exposure. All norovirus genotypes are associated with diarrheal 
disease, but GII.4 strains are thought to be more transmissible in healthcare 
settings, cause more severe disease, and are strongly associated with the 
seasonal patterns in reporting[23, 24]. The combination of the GII.4 variant 
pandemics, the association between GII.4 and more severe symptoms, and 
the high GII.4 infection rates among very young children shown in this study, 
could potentially explain the increase of norovirus disease reports since 2002. 
A potential bias in this study is that young children have not yet build up an 
immune response against norovirus and therefore are likely susceptible to any 
strain with matching receptor specificity, while adults have already been exposed 
multiple times to norovirus. Conclusions based on the seroprevalence among 
young children can therefore not be one-to-one translated to adults. 
We also observed broadening of the antibody profile in young children with 
increasing age, and reactivity to antigens representing genotypes that are rarely 
found in the Dutch national molecular surveillance. While we cannot rule 
out that this broadening of antibody profile reflects asymptomatic infections, 
another explanation is that these effects are caused by high-affinity antibodies 
directed against shared epitopes on the P domain of VP1, produced by B 
cells that undergo somatic hyper mutation and clonal selection upon multiple 
exposures to different genotypes. Although most conserved epitopes are found 
on the S domain of VP1, the B-cell supernatants in this study and studies with 
monoclonal antibodies have shown that the P domain contains conserved 
epitopes as well[25]. An important question is if such antibodies influence the 
susceptibility to subsequent infection, as has been observed with the discovery 
of broadly reactive non-hemagglutination inhibition antibodies in influenza A[26]. 
The shifting of antibody profiles for the different cohorts shows that a GI 
genotype was dominant in 1963 and a GII other than GII.4 in 1983, which may 
indicate that multiple dominant genotype switches have taken place before the 
predominance of GII.4 viruses. Although the overall norovirus seroprevalence 
did not change over the years in this study, it seems likely that genotype 
replacements may have concurred with a temporary increase in outbreak activity 
as is seen with GII.4 variant replacements[27]. Further studies are warranted to 
measure the effect of changes in the norovirus epidemiology on the norovirus 
incidence in the population and related costs for the society. 
Chapter 4
100
4
The first norovirus vaccine candidates have been tested in clinical trials and 
have shown to curb severity of disease after challenge with a homologous 
strain which may be helpful to reduce hospital admissions in vulnerable patient 
populations and reduce associated costs[28]. Field efficacy, cross-protection to 
drifted variants and heterologous genotypes, efficacy in various age groups, 
and duration of protection needs to be evaluated in future studies. Most 
importantly, however, our data suggests that special attention needs to be 
paid to the potential for updating the vaccine composition following changes 
in the norovirus epidemiology. Current vaccine candidates are based on the 
norovirus epidemiology with dominance of GII.4, but with the recent emergence 
of GII.17 in Asia the vaccine candidates may need to be updated[29]. Continued 
surveillance and a better understanding of norovirus epidemiology is essential 
knowledge for an optimal vaccine design.
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Supplemental Figure S1 Paired sera of four norovirus RT-PCR confirmed patients (ages 5, 47, 17, 
and 12 y respectively) infected with GII.4 Den Haag 2006b (A), GII.4 New Orleans 2009 (B), GII.3 
(C), or GI.6 (D) tested against 7 different norovirus P particles on the protein array platform. 
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Supplementary Table S1 Recombinant norovirus antigens used to test sera on the protein array 
platform
Genotype Antigen type Accession number
GI.1 P particle M87661
GI.2 P particle AF435807
GI.6 P particle AF538678
GI.8 P particle AF538679
GII.3 P particle U22498
GII.4 P particle AY038600
GII.9 P particle AY038599
GIV.1 VLP AF414427
1963 1983 2006/2007
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Cohort
Lo
g2
 ti
tr
es
Supplemental Figure S2 Distribution of positive titres against any antigen among cohorts
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Abstract
Immunocompromised patients can suffer prolonged norovirus symptoms and 
virus shedding for many years. Little is known about the prevalence of chronic 
norovirus infection among solid organ transplant (SOT) recipients. In this study, 
2182 SOT recipients were retrospectively tested for chronic norovirus infection. 
The first and last norovirus positive faecal samples of SOT recipients were 
sequenced to distinguish between persisting infection and re-infection. Patient 
charts were reviewed to obtain data on health status and treatments.
In all, 101 of 2182 (4.6%) recipients were norovirus infected and 23 (22.8%) 
of these developed chronic norovirus infection. Chronic norovirus infection 
was found among allogeneic heart, kidney and lung transplant recipients. The 
median shedding period at the end of the study period was 218 days (range 
32-1164 days). This study shows that chronic norovirus infection is not a rare 
phenomenon among SOT recipients in a tertiary-care hospital. Further research 
is needed to study the risk of norovirus transmission to other immunocom-
promised patients in the hospital and to the general population.
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Introduction
Noroviruses belong to the Caliciviridae and are the predominant viral cause 
of acute gastroenteritis in health-care institutions and community settings 
worldwide[1]. Noroviruses are a genetically and antigenically highly diverse 
group of positive stranded RNA viruses which can be subdivided in at least six 
genogroups (G) of which GI, GII, and GIV are known to infect humans[2]. Clinical 
symptoms of infected persons include watery diarrhea, stomach pain, vomiting, 
nausea, weight loss, as well as headache and fever. Norovirus outbreaks occur 
all year round but the frequency of outbreaks peaks in the winter season in 
temperate northern hemisphere countries. Norovirus is highly contagious and 
easily transmitted via person-to-person contact, contaminated surfaces, or via 
contaminated food or water[3]. 
In immunocompetent individuals, symptoms are self-limiting and usually 
resolve within 2-3 days[4]. Virions are shed in highest quantities during the acute 
phase of infection and shedding continues after symptoms have disappeared. 
Human challenge studies have shown that the median viral shedding in healthy 
adults is 28 days (range 13-56 days)[5]. In recent years, anecdotal reports have 
described norovirus as a causative agent of persisting infections in the immuno-
compromised host, including solid organ transplant recipients, patients with 
congenital immunodeficiency, patients treated with chemotherapy, and patients 
infected with human immunodeficiency virus (HIV)[6-10]. These patients can 
suffer from prolonged symptoms that may last multiple years leading to severe 
dehydration, malnutrition, patient discomfort, acute renal failure, and eventually 
death[11, 12]. Norovirus has parallels to hepatitis E virus that originally was 
thought to cause solely acute infection and for which recently has been shown 
to cause chronic infection among SOT recipients[13]. Patients with a chronic 
norovirus infection pose a potential public health risk since they shed virus in 
high quantities, may act as a reservoir for nosocomial transmission, and may be 
reservoirs for the development and emergence of new antigenic variants in the 
general population[14-16].
Improved immunosuppressive drugs have significantly reduced the incidence 
of organ rejections among SOT recipients and drastically improved patients’ 
survival with the consequence of a higher susceptibility to reactivation of latent 
infections, and hospital and community acquired infections[17, 18]. The higher 
infection rates among SOT recipients might be caused by the improved survival 
time[19]. The effect of immune suppression on the incidence of chronic norovirus 
infection has not been studied comprehensively, as information is limited 
to case reports and small series[20]. We hypothesize that chronic norovirus 
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infection is more common among SOT recipients than currently recognized. 
This retrospective cohort study aims to systematically estimate the incidence 
of chronic norovirus infection among patients with solid organ transplantations 
in a tertiary care hospital and to get better insight in the patient population 
susceptible to chronic norovirus infection.
Materials and methods
Study population
The Erasmus Medical Center (EMC) and affiliated hospitals comprise a 
1332-bed university medical centre. During the study period between January 
2006 until December 2014, 2182 patients received at least one lung, liver, 
kidney, or heart transplant. 
Data and sample collection
We retrospectively retrieved sex, date of birth, date of transplantation, date 
of hospital admission, and type of transplanted organ of all SOT patients 
during the study period from the hospital patient database. Next, we retrieved 
norovirus RT-PCR results of SOT patients who had a faecal sample routinely 
tested from the laboratory database. The collection of anonymized data and 
biobanked specimens was approved by the Erasmus MC ethical committee 
(MEC-2015-053). Norovirus RT-PCR was routinely implemented for diagnostic 
purposes in 2006 and used throughout the years. Recipients with at least one 
norovirus RNA positive sample post transplantation were assigned as norovirus 
infected. The first and last available faecal samples of patients with minimal two 
norovirus positive samples and minimal time between sampling moments of one 
month were retrieved from the hospital biobank, and sequenced to determine 
the norovirus genotype and to distinguish between chronic infections and 
reinfections. All faecal samples used in this study had been sent to the hospital 
laboratory for diagnostic purposes and stored at -80° C until further use. A 
database search was performed to obtain Clostridium difficile diagnostic requests 
of norovirus positive patients to get a better understanding of potential missed 
norovirus positive samples. We assumed that patients with a C. diff. diagnostic 
request (test negative) have symptoms of gastroenteritis. Therefore, patients with 
norovirus diagnosis without follow up, but who were repeatedly tested for C. 
diff. might reflect missed chronic norovirus patients. The samples submitted for 
C. diff. were not stored in the EMC biobank and could therefore not be tested 
for norovirus. Dutch norovirus surveillance data was retrieved from the noronet 
database (www.noronet.nl).
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Virus detection
Norovirus was detected with a routine semi quantitative real time Polymerase 
Chain Reaction (RT-PCR) assay as described[21]. Briefly, a faeces suspension was 
prepared with 100 mg or 200 µl faecal sample in 600 µl STAR buffer (Roche 
Diagnostics, Basel, Switzerland) and 80 µl chloroform. After centrifugation, 
190 µl of supernatant, 250 µl of lysis buffer (Roche Diagnostics) and 10 µl of 
an internal extraction control (phocine distemper virus) were transferred to a 
MagnaPureLC (Roche Diagnostics) for total nucleic acid (TNA) isolation. 20 µl 
viral RNA was amplified using the TaqMan Fast Virus 1-Step Master Mix (Life 
Technologies, Carlsbad, California, United States), primers, and uracil-N-glyco-
sylase (Life Technologies) in a final volume of 50 µl according to manufacturer’s 
instructions. The cycle threshold (Ct) value of both, the positive control sample 
and the internal extraction control, should be within the range of three standard 
deviations from the mean to approve a PCR run. 
Virus sequencing
A newly developed protocol was used to sequence a fragment of approximately 
~1000 bp overlapping ORF1 and ORF2 thus enabling genotyping of both 
the polymerase and capsid gene with a single protocol as recommended by 
Kroneman et. al. 2013[22]. After RNA extraction by MagNA Pure 96 (Roche 
Diagnostics), 5 µl viral RNA was reverse transcribed into cDNA in a total 
volume of 10 µl using 2.5 µM primer A (Supplementary Table 1), 1x RT-Buffer, 
0.1 mM dNTPs, 5 mM DTT, 20 units Rnase Out, and 100 units SuperScript 
III enzyme (Thermo Fisher, Waltham, USA) at subsequently 22° C for 10 min, 
50° C for 1 hour, and 95° C for 5 min. An outer PCR reaction was performed on 
2.5 µl cDNA in a total reaction volume of 25 µl using 1x HotStarTaq mastermix 
(Qiagen, Hilden, Germany), 1 µM primer A and 1 µM primer B for genogroup I 
(GI) viruses and 1 µM primer A and 1 µM primer C for GII viruses at 15 min 95° 
C, 30 cycles 94° C 30 s, 42° C 30 s, 72° C 90 s, followed by 72° C for 300 s. A 
nested PCR was performed on 1.5 µl PCR products in a total reaction volume of 
25 µl using 1x HotStarTaq mastermix and 1 µM primer D and E for GI, or 1 µM 
primer F and G for GII at 95° C 15 min, 4 cycles 94° C 30s, 55° C 30s, 72° C 
90s, followed by 32 cycles 94° C 30s, 60° C 30s, 72° C 90s, and subsequently 
72° C for 90s. PCR products were subsequently sequenced using ABI Prism 
BigDye Terminator v3.0 ready reaction cycle kit (Applied Biosystems, Bleiswijk, 
the Netherlands) using primers H-K. 
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Data analysis and clinical definitions
A chronic patient was defined as a recipient with at least two norovirus RT-PCR 
positive faecal samples, positive for ≥30 days, with an identical ORF1 and 
ORF2 genotype in the first and last sample, and clustering of both samples 
in a phylogenetic tree. Patients with at least two norovirus RT-PCR positive 
faecal samples, positive for ≥30 days, but not with an identical ORF1 and ORF2 
genotype or clustering of both samples in a phylogenetic tree were attributed 
as re-infected. Sequence trace files were analyzed using BioNumerics v7.5 
(Sint-Martens-Latem, Belgium) and genotyped by the norovirus genotyping 
tool[23]. Phylogenetic analysis was done based on maximum likelihood analysis 
and the Kimura 2-parameter model and 1000 bootstrap replicates using MEGA 
v6.0[24]. The Kimura 2-parameter model showed to be the best-fit substitution 
model as determined by the model selection module of MEGA v6.0. Norovirus 
sequences were submitted to Genbank (accession numbers: KX446494 
- KX446537). 
Results
A total of 2182 SOT recipients were included in the study: 174 heart- (HTx) 
of whom 10 were <10 years of age, 106 lung- (LungTx), 378 liver- (LiverTx), 
1510 kidney- (NTx) of whom 39 were <10 years of age, and 14 multiple organ 
transplant recipients (Table 12). The treating clinician decided to obtain a sample 
for norovirus diagnosis post transplantation based on the clinical presentation of 
the patient for 546 of 2182 (25.0%) recipients. One hundred one of 2182 SOT 
recipients (4.6%) tested positive for norovirus by RT-PCR at least once post 
transplantation (Figure 1A and Table 1). Thirty SOT recipients with norovirus 
(29.7%) were sampled more frequently with a minimal collection span of 
one month, and chronic infection could be confirmed by sequence analysis in 
23 of these (76.7%) (Supplementary Figure 1). Three persons (10.0%) were 
re-infected, and for 4 of 30 SOT recipients (13.3%) samples were not available 
or could not be sequenced due to low viral load. Chronic norovirus infection was 
identified among NTx (recipients <10 years of age n=5, ≥10 years of age n=15), 
LungTx (n=2), HTx (n=1, recipient <10 years of age), and not among LiverTX or 
multiple SOT recipients. 
Initial norovirus diagnostic testing was requested for unexplained diarrhea for 
21 of 23 (91.3%) recipients and for 2 of 23 (8.7%) this data could not been 
retrieved from the hospital medical records (Table 2). Symptoms of diarrhea 
or normal stool alternated with diarrhea were reported for 14 of 23 (60.9%) 
recipients during the course of the chronic period for at least 2 weeks post initial 
sampling. For two (8.7%) patients feeding disorder (n=1) and constipation (n=1) 
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Figure 1 (A) Study diagram, EMC = Erasmus Medical Center, NoV = norovirus. (B) Number of (test 
negative) diagnostic requests for C. diff. indicative for diarrheal symptoms among norovirus positive 
SOT recipients that had only been tested once (n = 75). 
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Table 1 Overview of norovirus infections among SOT recipients, 2006-2014.
Transplant Recipients RT-PCR confirmed 
NoV infection
Confirmed chronic 
NoV infection
n n % n %
Heart 174 9 5.17 1 0.57
Liver 378 5 1.32 0 0.00
Lung 106 9 8.49 2 1.89
Kidney 1510 77 5.10 20 1.32
Multiple* 14 1 7.14 0 0.00
Total 2182 101 4.62 23 1.05
*Multiple transplants: ten liver and kidney, two lung and kidney, and two heart and kidney.
were reported during follow-up which might be related to norovirus infection. 
Six recipients (26.1%) did not report norovirus related symptoms during the 
course of the chronic NoV episode and data was missing for the remaining 
recipient (4.3%). The median viral shedding period at the end of the study 
period for chronic patients lasted a median of 218 days (range 32-1164) (see 
Table 2 and supplementary Figure 2). 16 of 23 (69.6%) SOT recipients with 
sequence confirmed chronic norovirus infection shed norovirus for more than 
90 days. The median time span between transplantation and initial sampling 
was 301 days (range: 26-7387). All 23 chronically infected SOT recipients had 
been treated with mycophenolate mofetil (MMF) as initial immunosuppressive 
therapy in combination with tacrolimus or sirolimus, and 20 of 23 (87.0%) 
recipients were using corticosteroids. Thirteen of 23 (56.5%) of recipients 
needed a major change in the immunosuppressive therapy regime during the 
norovirus chronic period.
As norovirus testing is not always done as part of the routine evaluation of 
diarrhea in transplant recipients, we reviewed the diagnostic requests for 
C. diff., as a proxy for being symptomatic. In the month before initial norovirus 
detection, stool samples of 9 of 23 (30.4%) chronic norovirus cases had 
been sent to the laboratory for C. diff. testing, and in the month after the last 
norovirus positive stool test, this was done for 2 of 23 (8.7%) chronically 
infected recipients (Supplementary Figure 2). To get a better understanding 
of potential missed chronically infected norovirus recipients, we analysed the 
number of diagnostic requests for C. diff. with negative test outcomes, for 
the norovirus positive SOT recipients that had only been tested once (n=75, 
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Figure 1A). Repeated C. diff. testing had been requested for 33 of 75 (44.0%) of 
these patients, indicative for prolonged periods of unexplained symptoms and 
potentially missed chronic norovirus cases (Figure 1B). 
The virus diversity observed in the chronic patients was similar to that observed 
in the national surveillance data (Supplementary Figure 2). Only recipient 
number 3 and 16 were infected by a GII.4 variant that was not widely present at 
that moment in the Netherlands. Surprisingly, recipient 3 was infected by GII.P4 
New Orleans 2009-GII.4 New Orleans 2009 early 2008, almost a year before 
this variant was first detected in the surveillance. Three recipients had repeated 
infections: they switched from genotype GII.P4-GII.4 to GI.P7-GI.7, GII.
P4-GII.4 to GII.Pe-GII.4, and GII.P4-GII.4 to GI.Pb-ORF2 unknown (this could 
not be sequenced due to a low viral load, data not shown).
Discussion
This study has examined the incidence of (chronic) norovirus infection among 
the total population of solid organ transplant recipients in a tertiary care 
hospital. We found 4.6% of SOT recipients to be norovirus infected. Chronic 
norovirus infection was found among 23 of 2182 (1.1%) SOT recipients and 
shows that chronic norovirus infection is not a rare phenomenon. This study 
more than doubles the number of chronic norovirus cases described in the 
literature (Supplementary Table 2). Strengths of this study are the size of the 
patient cohort, and the confirmation of chronic infection by genome sequencing. 
Among SOT patients, chronic norovirus infection has been reported in literature 
among pancreas, renal, heart, liver, intestine transplant recipients, and among 
multi solid organ or a combination of solid organ and stem cell transplant 
recipients (Supplementary Table 2). Other studies reported chronic diarrhea 
related to norovirus among SOT recipients, but without distinction between 
persisting and re-occurring infections through sequencing[25-27]. 
This study had a retrospective setup and relied on the decision of a clinician to 
request for norovirus diagnostics. A limitation of the study is that the reported 
incidence rate therefore should be interpreted as a lower limit and presumably 
more chronically infected patients and longer shedding periods would have been 
identified with more frequent and systematic sampling, as was suggested by the 
more frequent (test negative) diagnostic requests for C. diff.. Furthermore, an 
unknown proportion of recipients change hospital over time, which potentially 
caused an underestimate of the prevalence as well. 
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Table 2 Characteristics of SOT recipients with confirmed chronic norovirus infection
Confirmed  
recipients (n=23)
Characteristic
Median age in years (range) 53 (2-72)
HTx recipients <10 years of age 1 (4.3%)
NTx recipients <10 years of age 5 (21.7%)
LungTx ≥10 years of age 2 (8.7%)
NTx recipients ≥10 years of age 15 (65.2%)
Number of females (males) 9 (14)
Median days between Tx and first NoV positive sample (range) 301 (26 -7387)
Median days viral shedding sequence confirmed (range) 218 (32-1164)
Initial diarrhea symptoms 21 (91.3%)
Initial symptoms not recorded 2 (8.7%)
Tested norovirus negative post chronic period 2 (8.7%)
Mortality (not related to norovirus infection) 3 (13.0%)
Initial immuno suppressive therapy
Mycophenolate mofetil 23 (100%)
Tacrolimus 22 (95.7%)
Sirolimus 1 (4.3%)
Basiliximab 1 (4.3%)
Corticosteroids 20 (87.0%)
Follow-up
  Symptoms > 2 weeks after initial diagnosis
Diarrhea symptoms 7 (30.4%)
Occasional diarrhea symptoms 7 (30.4%)
Feeding disorder 1 (4.3%)
Constipation 1 (4.3%)
No complaints reported 6 (26.1%)
No data about symptoms available 1 (4.3%)
  Immunosuppression
Major changes immunosuppression due to diarrhea symptoms 13 (56.5%)
Reason change immunosuppression not reported 5 (21.7%)
No changes immunosuppression 5 (21.7%)
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All recipients with chronic norovirus infection and available medical record 
information initially showed prolonged symptoms of diarrhea while during 
follow-up some patients reported continuous symptoms of diarrhea and others 
only diarrhea alternated with normal stool samples or even absence of norovirus 
related symptoms. This mixed presentation shows that diagnosis of norovirus 
infection in organ transplant patients based on clinical symptoms is complex. 
Diarrhea is a common complication that can be caused by treatment, Graft 
versus Host Disease (GvHD), multiple viral, parasitic, or bacterial infections, 
or a combination of these[28]. Since different aetiologies require fundamentally 
different treatment regimens, reliable diagnostic assays are an essential tool 
to distinguish norovirus infection from other causes of gastroenteritis[29]. Early 
recognition of norovirus infection among immunocompromised patients may 
help to fine-tune the immunosuppressive therapy, prevent uncomfortable 
medical examination like colonoscopy and biopsies, prevent norovirus 
transmission, improve the quality of life of patients, and reduce healthcare 
costs[30]. 
Despite the immunocompromised state leading to chronic infection, 3 SOT 
recipients apparently cleared the infection, but were re-infected. It is conceivable 
that the level of immunosuppression fluctuates, as this is tuned by the treating 
physician based on evaluation of engraftment. Unfortunately, we could not 
retrieve this information from the clinical records to address this question with 
certainty. Two patients were re-infected with a virus belonging to another 
genogroup, which is what would be predicted as within genogroup protective 
immunity of short duration which has been shown earlier in naturally infected 
healthy individuals in a one year cohort study from Cameroon[31]. 
In conclusion: chronic norovirus infection is not uncommon among SOT 
patients and studies are needed to get a better understanding of the patient 
populations at risk and clinical consequences for chronic norovirus infection, to 
study the risk of norovirus transmission to other immunocompromised patients 
and the general population, and to development an antiviral therapy for the 
treatment of norovirus infection. Hospitals need to consider improvement on 
early recognition of chronic norovirus infection and infection control measures to 
prevent transmission to the vulnerable immunocompromised patient population.
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Supplementary Table 1 Primers designed for norovirus GI, GII, and GIV RNA genome amplification 
and sequencing.
Code Genogroup Sequence Use
A GI and GII AIYTTICCIGCIGWRAAIGCRTT Reverse transcription / 
amplification
B GI ATGAAYACAATNGARGAYGGNCC Amplification
C GII ATGAAYATGAAYGARGAYGGNCC Amplification
D GI GACTACAGCTTGGGAYTCNACNCAR Amplification
E GI ACTCTCATATTCCCAACCCANCCRTTRTACAT Amplification
F GII GACTACTCTCGGTGGGAYTCNACNCAR Amplification
G GII ACCTCAAAACCACCTGCATANCCRTTRTACAT Amplification
H GI ACTCTCATATTCCCAACCC Sequencing
I GI GACTACACAGCTTGGGA Sequencing
J GII ACCTCAAAACCACCTGCAT Sequencing
K GII GACTACTCTCGGTGGGA Sequencing
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Supplementary Table 2 Molecular evidence for chronic norovirus infection among SOT patients 
as described in literature
First author Transplant Genotype (RT)-PCR 
confirmed 
patients
Patients 
confirmed 
by sequence 
analysis
Nilsson[1] Heart GII 1 1
Kaufman[2] Intestine GII.P4 1 0
Florescu[3] Small bowel NR 1 0
Lee[4] Combined liver, pancreas, and small 
bowel
NR 1 0
Westhoff[5] Kidney 2 GII 2 0
Schorn[6] Kidney 4 GII.P4, 3 GII.
P4-GII.4, GII.P7, 
GII.17
9 9
Ebdrup[7] Heart NR 1 0
Boillat-Blanco[8] Lung combined with hematopoietic 
stem cell Tx
GII.4* 1 1
Roos-Weil[9] Kidney 8 GII.4, GII.2, 
2 GII.6, GI.3, 3 
GII** 
15 0
Engelen[10] Heart NR 1 0
Hoffman[11] Small bowel GII.4 1 1
Chagla[12] Combined Kidney and Pancreas GII.4** 1 1
Echenique[13] Pancreas GII.4 1 1
Subtotal 36 14
This study Kidney, Lung, Heart 14 GII.P4-GII.4, 
3 GII.Pe-GII.4, 
2 GII.P21-GII.3, 
2 GII.P7-GII.6, 
GII.P7-GII.7, GII.
P2-GII.2 
30 23
Total 66 37
*Infection started before lung transplantation
**This study did not report whether genotypes are indicated for ORF1 or ORF2
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Supplementary Figure 1 Maximum likelihood phylogenetic analysis of partial polymerase and 
partial capsid norovirus sequences (938 bp) collected from the first and last available sample of 
n=22 SOT patients using the Kimura 2-parameter model for nucleotide substitution and 1000 
bootstrap replications. Indicated days are days relative to the sample date of the first positive sam-
ple for each individual patient. Patient number 3 (GII.P4 New Orleans 2009 - GII.4 New Orleans 
2009, 548 days RT-PCR positive) was excluded from the figure
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Supplementary Figure 2 Time line chronically norovirus infected SOT recipients (n = 23) and com-
parison to Dutch national surveillance norovirus GII.4 variants. Dark grey boxes indicate period of 
sequence confirmed chronic infection. Light grey box indicate norovirus RT-PCR positive period for 
patients with samples that could not be sequenced due to limited availability or low viral load. Circle 
symbols indicate diagnostic requests for C. diff. as an indication for symptoms of gastroenteritis and 
potential missed norovirus diagnosis. The arrows indicate years for which the contribution of GII.4 
variants was more than 10% of all GII.4 variants. GII.Pe is shown in the graph since this polymerase 
genotype recombines frequently with the capsid of the GII.4 Sydney 2012 variant. GII.4 variant 
abbreviations: NO = New Orleans, DH = Den Haag, NA = Not Assessed, A = Apeldoorn.
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Abstract 
The genus Norovirus comprises large genetic diversity and new GII.4 variants 
emerge every 2-3 years. It is unknown in which host these new variants 
originate. Here we study whether prolonged shedders within the immunocom-
promised population could be a reservoir for newly emerging strains. Faecal 
samples (n=65) from immunocompromised patients (n=16) were retrospectively 
selected. Isolated viral RNA was enriched by hybridization with a custom 
norovirus whole-genome RNA bait set and deep sequenced on the Illumina 
MiSeq platform. Patients shed virus for average 352 days (range: 76–716 days). 
Phylogenetic analysis showed distinct GII.4 variants in 3 out of 13 (23%) 
patients. The viral mutation rates were variable between patients, but did 
not differ between various immune status groups. All within host GII.4 viral 
populations showed amino acid changes at blocking epitopes over time and 
the majority of VP1 amino acid mutations were located at the capsid surface. 
This study found viruses in the immunocompromised host that are genetically 
distinct from viruses circulating in the general population and these patients 
therefore may contain a reservoir for newly emerging strains. Future studies 
need to determine whether these new strains are of risk for other immunocom-
promised patients and the general population.
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Introduction
Noroviruses are rapidly evolving positive stranded RNA viruses and are a 
predominant non-bacterial cause of acute gastroenteritis in all age groups 
worldwide[1]. The genus Norovirus demonstrates large genetic diversity and is 
divided into at least seven genogroups and subdivided into >30 genotypes[2]. 
Noroviruses evolve through recombination and through accumulation of 
mutations leading to changes in epitopes targeted by protective antibodies 
(antigenic drift). Antigenic drift has been observed for several genotypes but is 
most prominent in the predominant lineage genogroup II, genotype 4 (GII.4), 
of which a new antigenic variant arises and typically replaces the previously 
established variant every 2-3 years[3]. In the last two decades, six distinct GII.4 
variants emerged with global spread: US 1995/96, Farmington Hills 2002, 
Hunter 2004, Den Haag 2006b, New Orleans 2009, and Sydney 2012[4]. The 
evolution of norovirus GII.4 follows a stepwise or epochal pattern with limited 
genetic diversity within variants and large genetic distance, up to 25 amino 
acid (aa) mutations in the 541 (4,6%) aa VP1 protein, between variants[5]. Most 
genetic variation occurs in the protruding (P) domain of the VP1 protein, which 
is exposed to the outer surface of the capsid and shown to contain blockade 
epitopes and the receptor binding pocket[6]. The emergence of epidemic GII.4 
variants has been associated with a significant increase in the number of 
outbreaks leading to an increase in morbidities and mortality in risk groups 
including children, elderly, and immune compromised patients, and related 
costs for society[7-9]. 
Intermediate strains that fill the genetic gap between successive GII.4 variants 
are rarely detected which raise questions on how and where these strains 
emerge. Noroviruses circulating in animal reservoirs have been suggested as a 
source of norovirus variation. Although some animal genotypes are relatively 
closely related to human genotypes, GII.4 strains are rarely found in animals, 
making zoonotic introduction an unlikely hypothesis for the observed pattern of 
evolution of GII.4[10, 11]. Therefore, it is tempting to suggest that norovirus GII.4 
diversity originates within the human population. The immune compromised 
host is a potential reservoir for norovirus variants[12]. While norovirus infection 
is self-limiting in immuno-competent hosts, it is increasingly recognised that 
immune compromised individuals can suffer prolonged symptoms and can 
shed noroviruses for long periods of time, up to years. The failure to clear the 
virus coupled with high viral loads may result in substantial sequence diversity 
within a single chronic patient[12], but an important question is whether chronic 
norovirus shedders have sufficient (mucosal) immunity to drive selection of 
antigenic variants. Incidental evidence suggests changes in viruses over time 
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in these patients, including aa changes in B-cell epitopes, but only a limited 
number of patients were assessed[13-15]. 
In this study, we asked if patients with chronic norovirus infection (chronic 
shedders) could be a reservoir for genetically distinct variants. A selection of 
stool samples collected from 16 patients during a time span of 6.5 years was 
deep sequenced to analyse norovirus evolution within patients over time. 
Methods
Study population and sample selection
Faecal samples (n=65) of immune compromised patients (n=16) were retrospec-
tively selected from the Erasmus Medical Center biobank and screened for 
chronic infections. Solid organ transplant (SOT) patients with chronic norovirus 
infection were derived from an earlier study on the prevalence of chronic 
norovirus infection in a tertiary care hospital and additional screening was 
performed for non-SOT immune compromised patients[16]. For each patient, we 
selected the first and last known norovirus positive sample as a minimum, as 
well as intermediary samples, depending on availability. All samples had been 
obtained for diagnostic purposes and tested positive for norovirus RNA by an 
in-house standard diagnostic RT-PCR assay with Ct<32. Samples were stored 
at -80°C freezer. The Erasmus MC ethical committee approved the study under 
registration number MEC-2015-025. 
Viral RNA isolation
A clarified 10% (w/v) faecal suspension was prepared in PBS and viral RNA 
was extracted from 140 µl of the suspension using the Qiamp viral RNA 
mini kit (Qiagen, Hilden, Germany). The RNA extract (40 µl) was concen-
trated using a vacuum concentrator Savant Speed to 11 µl and used for first 
strand cDNA synthesis, using random hexamers and Superscript III Reverse 
Transcriptase (Thermo Fisher Scientific, Waltham, MA). The resulting cDNA 
was used for double stranded DNA synthesis using NEBNext mRNA Second 
Strand Synthesis Module (NEB, Ipswich, MA) according to the manufac-
turer’s instructions. Double stranded DNA was purified and concentrated 
with Genomic DNA clean and concentrator kit (Zymo research, Irvine, CA) 
with a final 30 µl elution. The DNA yield was quantified using a Qubit® 2.0 
Fluorometer (Invitrogen, Carlsbad, CA).
SureSelect target enrichment and library preparation for next generation sequencing
Overlapping 120-mer RNA baits complementary to and spanning partial or 
complete reference genomes of 987 norovirus strains were designed by the 
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PATHSEEK consortium[17]. The specificity of the baits was verified by nucleotide 
(nt) BLAST search against the NCBI Human Genomic Plus Transcript database. 
The custom designed norovirus bait library was uploaded to E-array and 
synthesised by Agilent Technologies. Norovirus cDNA samples, supplemented 
optionally with carrier G147 Human genomic DNA (Promega) to accomplish 
a total of 200 ng DNA, were sheared for 120 seconds using a Covaris E210 
(duty cycle 5%, Peak Incident Power 4 and 100m cycles per burst). End repair, 
non-templated addition of 3’ adapter ligation, hybridisation, enrichment PCR 
and all post-reaction clean-up steps were performed according to the SureSelect 
Illumina Paired-End Sequencing Library XT protocol[17]. All recommended 
quality steps were performed between steps.
Illumina sequencing
Libraries were multiplexed at 48 sample libraries per run. Paired end 300nt 
sequencing was performed on an Illumina MiSeq sequencer using the 600 
cycle v3 reaction kit. Base calling and sample demultiplexing were performed 
using the default settings on the MiSeq, generating paired FASTQ files for each 
sample.
De novo assembly and identification of viral genomes. 
Raw sequencing reads were processed to remove adapters and trimmed from 
the 3’ end to reach median Phred score >=35 using QUASR[18]. The reads were 
assembled into contigs using de novo assembly with SPAdes 3.9.0[19]. Calicivirus-
encoding contigs were identified with a modified SLIM algorithm combined 
with ublast[20, 21]. Partial but overlapping contigs were joined into full-length 
genome sequences using Geneious v9.0.4 (Biomatters Ltd) and ambiguities 
were resolved by directly counting 21 nt motifs containing the ambiguous site 
in the quality-controlled short read data. The python script used to check 
ambiguous sites is available at Github (https://github.com/mlcotten). Nt and 
aa uncorrected maximum pairwise distance between consensus sequences 
were calculated using MEGA v7.0.18[22]. Norovirus consensus sequences were 
submitted to GenBank (accession numbers: MF140633 - MF140697). 
Minimum-spanning network and Maximum-likelihood phylogenetic trees
All de novo assembled genomic sequences were aligned using AliView v1.16[23]. 
To investigate the clustering patterns, a minimum-spanning network within and 
between patients was constructed in PopART v1.7 (http://popart.otago.ac.nz/
index.shtml) with an epsilon of zero[24]. Maximum-likelihood phylogenetic trees 
were constructed in RAxML under GTR-Γ model of substitutions with 500 
bootstraps[25]. USEARCH version 7.0 was used to select representative GII.4 
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reference background sequences using a similarity cut-off of 98.6%[20]. The 
number of available GenBank reference sequences for GII.3, GII.6 and GII.7 was 
limited and therefore did not need to be reduced. 
Minor variant analysis
For each sample, the quality-controlled short reads were mapped to the 
assembled genome using BWA[26]. The resulting pileup file was parsed to 
identify positions with non-consensus nt. Only positions with a minimum 
coverage of 100 reads and only reads with minimum quality score of 35 were 
reported. Positions with >10% minor variant frequency were collected and 
graphed by genome position. While this threshold is relatively high, it was set 
to avoid over-interpretation of the data in view of contamination problems that 
have been reported for illumine platform based NGS (https://www.illumina.
com/content/dam/illumina-marketing/documents/products/whitepapers/
index-hopping-white-paper-770-2017-004.pdf?linkId=36607862). Our future 
work aims to optimize lower frequency variant calling based on NGS deep 
sequencing applications for clinical decision making. The python scripts used for 
the analysis and graphing are available at Github (https://github.com/mlcotten). 
Results
Patient profiling
Patients were sampled between 2008 and 2014, had an average age of 46 years 
(range: 3-72 years), and were infected with norovirus GII.P4–GII.4, GII.
Pe–GII.4, GII.P7–GII.6, GII.P7–GII.7, or GII.P21–GII.3 (Table 1). Patients were 
immune compromised due to solid organ transplantation (kidney n=8, lung 
n=2), allogeneic stem cell transplantation (n=2), leukaemia (n=2), or immuno-
logical disorders (n=2). The average norovirus shedding time (at the end of the 
study period) was 352 days (range: 76 – 716 days).
Quality control
For initial quality assessment, we compared the total number of reads, number 
of norovirus specific reads, and genome read depth for each sample in relation 
to the norovirus quantitative RT-PCR cycle threshold value (Supplementary 
Figure 1 panels A, B, and C). The total number of short reads per sample 
showed a median value of 311558 per sample, with the majority of reads norovi-
rus-specific (median value 91%), The median read depth of the full genomes 
was 4679. As expected given the use of a capture array, there was not a strong 
correlation between these three measures of sequencing performance and the 
input Ct value with performance only dropping at the highest Ct values. Four 
samples showed lower total reads and lower norovirus-specific reads (Patient 4 
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day 355, Patient 10 day 462, Patient 11 day 83, Patient 10 day 508). Several 
samples (Patient 4 day 355, Patient 9, day 121 and 176, Patient 10 day 508, 
Patient 12 (all four time points), and Patient 16 (day 0)) yielded more than one 
genome using de novo assembly suggesting either co-infection or technical 
contamination. Co-infection with another genotype from the study was excluded 
based on epidemiological data (sampling date) and clustering of samples in 
a minimum spanning tree, and technical contamination was the most likely 
explanation for these secondary genomes based on sequence batch number and 
genome coverage. In order to avoid over interpretation of the data, low coverage 
contigs were therefore removed from the analysis. As a measure of sample 
handling and quality control, a minimum spanning tree of all 65 genomes was 
constructed (Figure 1). Genomes clustered closely by patient in nearly all cases, 
although one group of patients (Patient 3, 4, 10) were infected with related 
viruses that showed some overlap in the tree. Maximum-likelihood phylogenetic 
trees of full genomes and each of the three ORFs were inferred (Supplementary 
Figure 2), showing similar consistent patterns of patient-derived genomes. 
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P15
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P13
Figure 1 Minimum spanning haplotype network constructed from 65 norovirus genome sequenc-
es, showing the relationship between genomes within and between patients in the study. Each 
node represents a genome and nodes are coloured by patient of origin with the length of vertices 
represents number of nucleotide changes (indicated within brackets) between pairs of genomes. 
The size of the node is proportional to the number of genomes clustered in the node. 
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Table 1 Cohort description
ID Age dT Month/
year 
first 
sample
Complaints 
of gastro-
enteritis 
since*
Group Norovirus genotype Underlying 
illness
Immunosup-
pressive therapy
1 56 716 Jan 2009 Dec 2008 SOT GII.P4 Apeldoorn 2007 
- GII.4 Apeldoorn 2007
Kidney 
 transplantation
MMF, Tacrolimus, 
corticosteroids
2 3 402 Mar 2012 Feb 2012 SOT GII.P4 New Orleans 
2009 - GII.4 New 
Orleans 2009
Kidney 
 transplantation
MMF, Tracrolimus
3 72 122 Apr 2013 Apr 2013 SOT GII.Pe - GII.4 Sydney 
2012
Kidney 
 transplantation
MMF, Tacrolimus, 
corticosteroids
4 44 355 Apr 2013 Mar 2013 SOT GII.Pe - GII.4 Sydney 
2012
Kidney trans-
plantation
MMF, Tacrolimus, 
corticosteroids
5 66 441 May 2013 May 2013 SOT GII.P7 - GII.6 Kidney trans-
plantation
MMF, Tacrolimus, 
corticosteroids
6 55 204 Nov 2011 Nov 2011 SOT GII.P4 Den Haag 
2006b - GII.4 Den 
Haag 2006b
Kidney trans-
plantation
MMF, Tacrolimus, 
corticosteroids
7 12 637 Feb 2011 Dec 2010 SOT GII.P21 - GII.3 Kidney trans-
plantation
MMF, Tacrolimus, 
corticosteroids
8 6 340 Jun 2012 Jun 2012 SOT GII.P4 New Orleans 
2009 - GII.4 New 
Orleans 2009
Kidney trans-
plantation
MMF, Tacrolimus, 
corticosteroids
9 58 176 Aug 2013 Dec 2012 SOT GII.P4 New Orleans 
2009 - GII.4 Not 
assigned
Lung trans-
plantation
MMF, Tacrolimus, 
corticosteroids
10 57 462 Jan 2013 Jul 2012 SOT GII.Pe - GII.4 Sydney 
2012
Lung trans-
plantation
MMF, Tacrolimus, 
corticosteroids
11 35 413 Jan 2013 Jan 2013 SCT GII.P4 New Orleans 
2009 - GII.4 Sydney 
2012
Allogeneic 
stem cell trans-
plantation
MMF, corticos-
teroids
12 36 76 Jul 2013 Jun 2013 He-
mato
GII.P7 - GII.7 Follicular 
non-Hodgkin's 
lymphoma
Unknown
13 57 235 Dec 2010 Dec 2010 SCT GII.P4 New Orleans 
2009 - GII.4 New 
Orleans 2009
Allogeneic 
stem cell trans-
plantation
Cyclosporine, 
corticosteroids
14 48 109 Jan 2008 Jan 2008 He-
mato
GII.P4 Den Haag 
2006b - GII.4 Den 
Haag 2006b
Chronic 
lymphocytic 
leukaemia
-
15 71 495 Jun 2009 May 2009 Other GII.P4 Not assigned - 
GII.4 Hunter 2004
Good's syn-
drome
-
16 62 451 Jun 2010 Aug 2004 Other GII.P4 Not assigned - 
GII.4 Not assigned
Vasculitis Cyclophospha-
mide, Azathio-
prine, corticos-
teroids
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Figure 2 Maximum-likelihood phylogenetic tree constructed from 50 consensus VP1 nucleotide 
sequences of 13 patients with chronic norovirus GII.4 infection compared to 114 norovirus GII.4 
VP1 GenBank reference sequences. The reference sequences were coloured by GII.4 variant, black 
nodes represent sequences from patients with chronic infection, and salmon coloured shading 
indicates sequences derived from identical patients. 
Abbreviations Table 1 ID = Patient identifier, dT = duration of chronic infection in days as defined 
by the time between first and last  sample, SOT = Solid Organ Transplant , SCT = Stem Cell Trans-
plant, Hemato = Hematologic disease, MMF = Mycophenolate mofetil 
*as reported in the hospital patient database and subjected to the interpretation of the clinician 
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Figure 3 A) Within patient norovirus nucleotide and amino acid mutation rate. Average nucleotide 
and amino acid changes per day for norovirus full genome sequences derived from all 16 patients 
with chronic infection stratified per immune status (SOT = solid organ transplantation, SCT = stem 
cell transplantation, Hemato = hematologic disease). The changes were calculated by aligning nu-
cleotide or protein sequences and counting the number of differences between the initial and the 
query sequence. The elements of the plots include the values from individual genomes (gray dots), 
the median value for the set (thick black line), the interquartile range for the set (grey rectangle) 
and the lower and upper quartiles (horizontal black lines above and below the rectangle). 
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Figure 3 B) Accumulated nucleotide changes occurring in each patient plotted by genome posi-
tion. For each patient, all nucleotide changes from the initial consensus genome sequence were 
plotted by position (dark gray bar, and gaps are shown in light grey). The total number of days of 
observation for each patient is listed after the patient id. A diagram showing positions of the three 
major norovirus open reading frames (ORF) is shown at the top of each column.
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Figure 4 The norovirus P domain GII.4 Sydney 2012 dimer structure (PDB id 4OP7, download-
ed from http://www.rcsb.org/pdb) with the within-host changes in aa residues that occurred 
between the first and last sample coloured in red and deletions in orange. The reference structure 
shows epitopes A, D, and E in yellow. Numbers above the protein models indicated study patient 
identifier numbers. Dark grey and grey indicate both monomers that form the P domain dimer and 
blue indicates a glycan structure that functions as the norovirus (co-) receptor. The PyMOL Molec-
ular Graphics System version 1.8 (Schrödinger, LLC) was used to localise amino acid residues. 
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A A A A A A D D D E E E
PatientID  Sequence_ID 294 296 297 298 368 372 393 394 395 407 412 413
p1 E7800007_p1_d0 T  S  R  N  A  D  N  T  A  S  N  S
p1 E1300272_p1_d566 T  S  H  S  N  N  G  -  T  S  N  I
p1 E7800016_p1_d716 S  T  H  R  D  S  G  -  T  S  S  T
p2 E1300296_p2_d0 P  S  H  N  A  D  S  T  T  S  N  I
p2 E1300297_p2_d402 P  S  R  N  A  D  S  T  T  S  N  I
p3 E1300301_p3_d0 T  S  R  N  E  D  S  T  T  S  N  T
p3 E1300302_p3_d72 T  S  R  N  E  D  S  T  T  S  N  T
p3 E1300303_p3_d122 T  S  R  N  E  D  S  T  T  S  S  T
p4 E1300308_p4_d0 T  S  R  N  E  D  S  T  T  S  N  T
p4 E1300309_p4_d355 T  S  R  N  E  D  S  T  T  S  S  T
p6 E1300319_p6_d0 A  S  R  N  S  E  G  T  T  S  D  V
p6 E1300320_p6_d18 A  S  R  N  S  E  G  T  T  S  D  V
p6 E1300321_p6_d204 A  S  H  N  E  K  G  T  T  S  D  V
p8 E7800011_p8_d0 P  S  R  N  A  D  S  T  T  S  N  I
p8 E1300329_p8_d173 P  S  H  N  A  N  D  T  T  S  N  I
p8 E1300330_p8_d269 P  S  H  N  A  N  D  T  P  S  N  I
p8 E7800020_p8_d340 S  S  H  N  A  N  D  T  P  S  N  I
p9 E1300280_p9_d0 G  T  N  R  D  S  D  D  T  S  G  T
p9 E1300281_p9_d58 G  T  N  R  D  S  D  D  S  S  G  T
p9 E1300282_p9_d121 G  S  N  R  D  S  D  D  S  S  G  T
p9 E1300283_p9_d176 G  S  D  R  D  H  D  D  S  S  G  I
p10 E7800008_p10_d0 T  S  R  N  E  D  G  T  T  S  N  T
p10 E1300285_p10_d316 T  S  S  T  E  N  D  T  A  S  N  T
p10 E1300286_p10_d362 T  S  S  T  E  N  D  T  A  S  N  T
p10 E1300287_p10_d462 T  S  S  T  E  N  D  T  A  S  N  T
p10 E7800017_p10_d508 T  S  S  T  E  N  D  T  A  S  N  T
p11 E7800009_p11_d0 T  S  R  N  E  D  S  T  T  S  N  T
p11 E1300306_p11_d83 T  S  R  N  E  D  S  T  T  S  N  T
p11 E1300307_p11_d195 T  S  R  N  E  D  S  T  T  S  N  T
p11 E7800018_p11_d413 T  S  H  H  E  N  N  T  T  S  N  T
p13 E7800012_p13_d0 P  S  R  N  A  D  S  T  T  S  N  I
p13 E1300300_p13_d51 P  S  R  N  A  D  S  T  T  S  N  I
p13 E7800019_p13_d235 S  S  R  N  A  D  N  T  T  S  N  I
p14 E7800015_p14_d0 A  S  R  N  S  E  S  T  T  S  D  V
p14 E1300305_p14_d39 A  S  R  N  S  D  S  T  T  S  D  I
p14 E7800023_p14_d109 A  S  R  N  S  D  G  T  T  S  D  I
p15 E7800013_p15_d0 G  T  Q  S  S  S  S  T  T  E  D  S
p15 E1300263_p15_d41 G  T  Q  S  S  S  S  T  T  E  D  S
p15 E1300264_p15_d81 G  T  Q  T  S  S  S  T  T  E  D  S
p15 E1300265_p15_d102 G  T  Q  T  S  S  S  T  T  D  D  S
p15 E1300266_p15_d174 G  T  Q  T  S  N  S  T  T  E  D  S
p15 E1300267_p15_d215 G  T  Q  T  S  S  S  T  T  D  D  S
p15 E1300268_p15_d419 G  T  Q  T  S  S  S  T  T  D  D  N
p15 E1300269_p15_d476 G  T  Q  T  S  S  G  T  T  N  D  N
p15 E7800021_p15_d495 G  T  Q  T  S  S  S  T  T  E  D  N
p16 E7800014_p16_d0 G  T  H  D  H  N  D  -  N  D  G  T
p16 E1300288_p16_d101 G  T  H  D  H  T  D  -  N  D  G  T
p16 E1300289_p16_d202 G  T  H  D  H  N  D  -  N  D  G  T
p16 E1300290_p16_d403 G  T  H  D  H  T  D  -  N  D  G  T
p16 E7800022_p16_d451 G  T  H  D  H  T  D  -  N  D  G  T
Figure 5 Within-host aa changes of VP1 blockade epitope A, D, and E among longitudinal samples 
of 13 patients with chronic GII.4 infection[28]. Amino acid changes of GII.4 variant reference sequenc-
es are indicated on top. Gray shading indicates changed acid residues for each column and patient.
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Figure 6 Minor variant content. For each sample, the specific minor variant content was deter-
mined by mapping all quality-controlled reads to the final consensus genome from that sample 
(See Methods section). Only sites with >100 fold coverage and reads with Phred quality score of 
>35 were reported. Positions with non-consensus nucleotide at >10% frequency were graphed and 
the total number of positions with variants in each category are listed at the left of each panel. 
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Within-host genetic evolution compared to viral genetic diversity in the general 
population
To study within-host virus evolution, ORF2 consensus sequences from 
chronically infected patients were compared to ORF2 sequences derived from 
GenBank reference sequences using a maximum parsimony analysis (GII.4: 
Figure 2, and GII.3, GII.6, GII.7: Supplementary Figure 3A, 3B, and 3C, respec-
tively). Ten of 13 GII.4 infected patients (76.9%) were infected with viruses 
similar to known GII.4 variant clusters (Figure 2). However, three of 13 (23.1%) 
first patient specimens contained a virus with large genetic distance (97 of 1623 
nt (6,0%), 82 of 1623 nt (5,1%), and 135 of 1623 nt (8,3%), patients 9, 15, 
and 16, respectively) to closest known circulating GII.4 strain (as determined 
by nt BLAST search). Remarkably, these patients were first sampled in August 
2013, June 2009, and June 2010 (Patients 9, 15, and 16, respectively), but 
were infected with viruses closest to GII.4 New Orleans 2009, GII.4 Hunter, 
and GII.4 US95/96, respectively, which were predominant years before these 
patients were sampled. Patients 5, 7, and 12 infected with non-GII.4 norovirus 
strains were infected with strains with large genetic distance to reference strains, 
but this can be explained -in part- due to a limited number of available reference 
sequences (Supplementary Figures 3A, 3B and 3C). 
Viral mutation rate and the effect of immune status
Full genome consensus sequences were used to determine the within-patient 
average nt and aa changes per day (Figure 3A). The nt changes per day among 
individual patients showed variation from 0.03 to 0.37 nt / day, and 0.01 to 
0.21 aa / day and although variation among individuals was high, no significant 
mutation rate differences were observed between immune status groups (solid 
organ transplantation, stem cell transplantation, hematologic disease, or 
other). The positions of nucleotide changes across the norovirus genomes were 
examined. All nucleotide changes occurring during the entire observation period 
were plotted for each patient (Figure 3B). Changes were observed throughout the 
genome. 
Mutation hotspots in the P domain of VP1
A structure of the norovirus GII.4 Sydney 2012 P domain has been generated 
previously[27] and this model was used to locate within-host aa changes for 
each GII.4 infected patient individually (Figure 4). The majority of the observed 
aa changes were on the predicted outer surface of the P domain complex 
at or near epitope A, D, and E. A few aa changes were located more deeply 
within the P-domain structure: patient 3 V385A, patient 8 V385I, patient 9 
P305L, patient 11 R286K, and patient 13 L452I. To further study the effect 
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of within-host evolution on antigenic evolution and receptor specificity, aa 
positions for blockade epitopes A, D, and E, known for GII.4[28], are shown for 
13 GII.4 patients over time (Figure 5). The exact location of antigenic epitopes 
for genotype GII.3, GII.6, and GII.7 are unknown and therefore changes in the 
epitopes of the virus populations of patients (5, 7, and 12) were not determined. 
All patients showed to contain a virus population with at least one aa change 
during follow up in the antigenic epitopes (Figure 5). The insertion of epitope 
D position 394 is found in a highly variable loop region, located at the top of 
the P2 domain, and present among all GII.4 variants since Farmington Hills 
2002[29, 30]. Patient 16 was infected with a strain most related to GII.4 US95_96 
and therefore lacks this insertion in all specimens. Remarkably, patient 1 was 
infected with GII.4 Apeldoorn 2007, initially contained the insertion at position 
394, but lost it by day 566. Consensus ORF2 sequences of virus populations 
were also inspected for within-host mutations of the receptor binding pocket site 
I, II, and III: (GII.4: aa 343-347, aa 374, and aa 442-443, GII.6: aa 360 – 363, 
aa 389, and aa 452, GII3: aa 357-360, aa 386, and aa 450 – 451, GII.7: aa 
349 – 351, aa 378, and aa 446 – 447, respectively)[31]. None of the 16 patients 
contained a virus population that showed within-host aa changes in the receptor 
binding pocket sites and therefore none of the virus populations changed 
receptor specificity (data not shown).
Viral non-consensus minor variants
The minor variant diversity was plotted over time to study whether the minor 
variant diversity can be used as an indicator for chronic infection (Figure 6). 
Although the viral diversity is variable over time, the majority of the 16 patients 
showed increases in minor variant content over the observation period: 6 of 
16 patients showed consistent increase in the minor variant content with each 
longitudinal sample having more variants than the previous sample and 13 of 
16 patients had a final time point with more variants than first time point. Six 
patients started with high variant content (40 or more sites with >10% minor 
variant content, patients 5, 7, 9, 12, 15, 16) and may indicate that these patients 
were infected for some time before the initial sampling. Variation was observed 
throughout the genome suggesting that the variation was a consequence of a 
random process and not due to accumulation of changes as a consequence of 
selective pressure on specific proteins (data not shown). Furthermore, the minor 
variant content should be interpreted with caution as several samples showed 
evidence of contamination (see paragraph quality control). 
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Discussion
The aim of this study was to describe norovirus within-host evolution and 
diversity in chronically infected and immunosuppressed patients. We show that 
immunocompromised patients were initially infected by viruses which can be 
phylogenetically linked to strains found in the general population. However, 
over the observation time, the within-host virus populations evolve into virus 
populations that are genetically distinct and with mutations across the genome 
including the antigenic domains. Immunocompromised patients therefore 
contain a reservoir of viruses that are genetically and possibly antigenically 
distinct from viruses circulating in the general population. While similar 
observations have been reported for individual or small patient groups, we show 
that all chronic norovirus patients that we identified in our hospital had evidence 
of evolving viruses[12, 13, 15, 32-34]. 
Three of the GII.4 infected immunocompromised patients (patient: 9, 15, 
and 16) shed viruses with a large genetic distance to any norovirus available 
in public databases. These patients were likely infected some time (possibly 
years) before the initial sampling of this study or alternatively were infected by 
a strain transmitted from another immunocompromised patient (which was 
also not represented in the public database). For patient 16 there is evidence of 
long-term unexplained symptoms of gastroenteritis before the initial sample in 
June 2010. This patient was reported to have symptoms of gastroenteritis for 
the six previous years and in agreement with this observation the sample from 
2010 contained a virus strain with nearest ancestor to GII.4 US95/96 which 
was predominantly detected in the surveillance until 2002[5]. Thus, potentially 
this patient was infected with the same strain for at least six years before the 
sampling in the current study. The VP1 sequence from the last available samples 
of patient 9, 15, and 16 showed a similarity of 94%, 95%, 92% respectively 
with the closest known strains. There is not a strict distance criterion for new 
GII.4 variants, but currently recognised successive variants have nt similarity of 
>95%[33, 35]. However, the novel variants found in this study do not justify a new 
name since they are not yet found as epidemic strain in two geographic distinct 
regions[35]. 
It remains to be determined whether new virus variants found in immuno-
compromised patients are of risk for other patients or the general population. 
Transmission between immunocompromised patients has been reported earlier, 
but only in an early stage of infection with a maximum of 17 days after initial 
diagnosis[36, 37]. We have tried to retrospectively find transmission events in this 
study by linking epidemiological information (sampling date and hospital ward) 
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of positive samples from immunocompromised patients to positive samples 
obtained from other patients, but have not yet found transmission events (data 
not shown). This can however be a result of under-sampling of the hospital 
patient population and staff, as previously described[38]. It could also be that 
the viruses found in immunocompromised patients are highly adapted to their 
host and/or have a lower fitness due to the limited immune pressure and are 
therefore not easily transmitted to other humans. This could theoretically 
mean that immunocompromised patients are only infectious in an early stage 
of infection when the virus still maintains features necessary for infection in 
immunocompetent hosts.
A specific capture method was used to deep sequence the whole norovirus 
genome from clinical samples without the need for additional amplification 
steps; these methods have been successfully implemented for other viruses and 
bacteria[17, 39-41]. The method provided a high coverage across the full norovirus 
genome allowing for minor variant analysis with high sensitivity, in addition to 
analysis of the full genomes. 
The majority of patients had a viral population with an increasing minor variant 
content over time and therefore we concluded that an increased minor variant 
content is an indication for chronic infection as suggested by others[12, 42]. 
Patients shedding viruses with large genetic distance (patients 9, 15, and 16) also 
had a highly diverse variant content on day 0, which supports our conclusion 
that these patients were already infected some time before the initial sampling. 
Other patients already showed high diversity in the earliest samples or a more 
variable pattern over time, which might be explained by a missed norovirus 
infection with the earliest sequenced sample actually obtained after an unknown 
period of virus evolution in the suppressed patient, disease progression, or 
changes in the immunosuppressive therapy. The technical contamination as 
detected in some of the specimens, and quite commonly observed with Illumina 
deep sequencing, is a limitation of the quasi species analysis as presented in this 
study, but we have corrected for this as described in the methods section. 
There is currently no registered antiviral therapy available for norovirus infection 
and patients with dehydration or malnutrition caused by norovirus infection can 
only be treated with supportive treatment. It has been observed that a temporary 
pause in the immunosuppressive therapy could allow transient immune system 
recovery and help to clear the virus, but this should be done with great care 
since this entails a risk for organ rejection and is not an option for patients who 
are immunocompromised due to other causes[43]. In other studies, a limited 
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number of infected immunocompromised patients received experimental 
enterally administered immunoglobulin therapy as a treatment against chronic 
norovirus infection with mixed success rates[44-46]. With the results of this study 
we hypothesize that the success of immunoglobulin treatment depends on 
the antigenic distance between the within-host strain and the virus population 
circulating at the moment of immunoglobulin harvesting. Given the high 
within-host mutation rates as shown in this study, immunoglobulin treatment 
may only be successful when it is produced from plasma batches from local 
patients recovering from similar viruses and administered in an early stage of 
infection. Future prospective studies are needed to address this issue.
The number of immunocompromised patients has largely increased in the last 
few decades due to an increase in the number of allogeneic transplants. It was 
shown here that novel norovirus variants are developed in the immunocom-
promised host and future prospective studies are needed to assess the risks of 
transmission of this new strains to other immunocompromised patients and 
the general population and subsequent consequences for hospital infection 
control guidelines. In view of the frequent reports of hospital acquired norovirus 
infection, and the potential consequences in patients at risk for chronic 
norovirus infection, low-threshold screening for infection should be considered 
in high risk patient wards. 
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Supplementary Figure 1 Read yield quality control. The total number of reads for the 65 samples 
(A), the number of norovirus specific reads (B), and the average read depth of the resulting sample 
genome (C), were plotted as a function of the RT-PCR cycle threshold value Ct.
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Supplementary Figure 2 Maximum-likelihood phylogenetic trees constructed from 65 consensus 
full genome and ORF1, ORF2, and ORF3 nucleotide sequences obtained from 16 patients with 
chronic norovirus infection.
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Supplementary Figure 3 Maximum-likelihood phylogenetic tree constructed from 15 consensus 
VP1 nucleotide sequences of three patients (indicated in red) infected by norovirus GII.3 (patient 7 - 
day 0, 287, 365, 434, 533, 637) (A), GII.6 (patient 5 – day 0, 204, 308, 328, 441) (B), or GII.7 (patient 
12 – day 0, 26, 54, 76) (C), compared to VP1 GenBank reference sequences (indicated in black). 
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The general aim of this thesis was to get a better understanding of the global 
norovirus diversity, with a focus on the role of chronic norovirus infection on 
virus diversity, antigenic variation and evolution. The obtained knowledge can 
be used to predict severe norovirus outbreak seasons, is useful for improvement 
of hospital hygiene and infection control guidelines, and is relevant for future 
vaccine development.
Large norovirus genetic diversity
The norovirus genetic diversity is extremely large as outlined in the introduction 
of this thesis. New norovirus diversity is discovered on a regular basis: novel 
genogroups, genotypes, recombinants within and between genotypes, and 
antigenic drift variants have been found and described recently[1-7]. The 
distribution and incidence of norovirus genotypes changes over time and by 
geographic region, with GII.4 as the predominant genotype responsible for 
70-80% of the outbreaks detected worldwide during the last two decades[8-12]. 
Changes in the norovirus epidemiology have a large effect on the society since 
the emergence of novel drift variants goes hand in hand with an increase in 
the number of reported outbreaks, including the number of hospitalizations 
and deaths related to acute gastroenteritis[13-15]. We show in Chapter 2.1 that 
an increase in global norovirus reports late 2012 was related to the emergence 
of the novel GII.4 Sydney 2012 variant. This new GII.4 Sydney 2012 variant 
was the 6th in a row of variants with a global distribution since the start of 
norovirus molecular surveillance in the mid-1990s: US95/96, Farmington Hills 
2002, Hunter 2004, Den Haag 2006b, New Orleans 2009, and followed by 
GII.4 Sydney 2012[5, 16]. GII.4 Sydney 2012 remained the predominant strain 
during the following years, but this pattern was disrupted in some countries 
in Asia late 2014. A novel GII.P17-GII.17 (GII.17 Kawasaki 2014) replaced 
GII.4 among outbreaks of acute gastroenteritis in China and Japan during 
the Northern hemisphere winter of 2014/2015 and was detected widely in 
European countries in after years, as described in Chapter 2.2 and Chapter 3 
and by others[17-19]. This is a unique observation since the replacement of the 
predominant GII.4 has never been observed by molecular surveillance. It is an 
important finding since norovirus research always had a focus on GII.4 during 
the last two decades, although genotype replacements may have occurred 
in history before the molecular surveillance started (mid 1990s) as shown in 
Chapter 4 by using a multiplex serological assay. Interestingly, GII.17 has not 
yet become the predominant genotype worldwide in the summer of 2017 and 
no new GII.4 variants have originated since the emergence of GII.4 Sydney 
2012 in the 2012/2013 winter season, in contrast to what was expected 
following the observed pattern of the last twenty years. Some known genotypes 
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have caused (local) epidemics recently, like GII.P2-GII.2 and GII.P16-GII.2, 
and a new recombinant GII.4 Sydney 2012 (GII.16-GII.4 Sydney 2012)[20-23]. 
The replacement of the polymerase gene for the latter appears to have led to 
more efficient replication and/or transmissibility[6, 24, 25]. These observed rapid 
changes in norovirus genetic diversity raise concerns about the current vaccine 
candidates under development with GII.4 components and raise questions 
regarding the origin of norovirus diversity and the underlying mechanisms and 
evolutionary driving forces. 
Origin of norovirus diversity
The norovirus GII.4 evolutionary driving forces are well described: the human 
population builds up immunity against the outer surface of the major capsid 
protein which drives the selection of virus variants that can evade infection 
blocking antibodies via antigenic drift[26]. Population immunity is therefore the 
main norovirus evolutionary driving force. This process occurs in a stepwise 
manner, frequently referred to as epochal evolution[9]. The number of VP1 
amino acid (aa) changes between successive global GII.4 variants lies in the 
range of 21-25 aa[9]. In addition, GII.4 drift variants accumulate multiple 
mutations in the minor capsid protein compared to their precursors, likely 
to maintain capsid stability, and these mutations add up to the already large 
genetic jump of the VP1[27]. The main question here is: how and in which 
host does the virus acquire the mutations needed for a new drift variant? It is 
most likely that new GII.4 variants originate in the human population since 
GII.4 is widespread in the human population, evolutionary driving forces are 
driven by population immunity, and natural GII.4 infections among animals 
are considered to be very rare[28]. Despite its high mutation rate, it is not likely 
that the viruses could develop all mutations required for a new variant over the 
course of a normal infection in a single immunocompetent host since norovirus 
shedding usually lasts only four weeks. If we assume that multiple hosts 
are required for the development of new drift variants, it is unexpected that 
intermediate GII.4 variants are scarcely detected in the surveillance, although 
this could potentially be explained by the absence of norovirus surveillance 
in most countries. Norovirus surveillance is absent in almost all of Africa, 
South America, and in Asian countries except China and Japan as shown in 
Chapter 3, and only a very small fraction of sporadic cases and outbreaks is 
investigated by sequencing methods. Precursor drift variants could therefore 
be potentially missed by surveillance, especially when these strains are only 
spread in a restricted geographical area. An alternative hypothesis is that novel 
norovirus variants are developed within individuals with a chronic infection due 
to a diminished immune system. These chronic shedders can shed virus for 
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multiple years in extremely high quantities, which would provide enough time to 
accumulate all required mutations to develop a new drift variant within a single 
host. The potential for chronic norovirus shedding was considered to be rare 
until recently. In Chapter 5 we showed that long term virus shedding is more 
common among solid organ transplant patients than originally thought and we 
more than doubled the number of patients described in the literature. To get a 
better understanding of the potential for virus drift within prolonged shedders 
we studied the within host evolution of chronic shedders using next generation 
sequencing technology in Chapter 6. We showed that viruses within these 
patients evolve to highly divergent strains, with large genetic distance to known 
virus clusters including antigenic changes at the blockade epitopes over time. 
We therefore concluded that immunocompromised patients contain a reservoir 
for new norovirus genetic diversity. It however needs to be determined whether 
these new strains are transmissible to other individuals and are able to cause 
large epidemics or pandemics. 
It has been suggested that the level of immunosuppression of the host may 
determine the extent of viral evolution[29]. While the viral populations of severely 
immunocompromised individuals show a very high viral diversity in contrast to 
viral populations found among healthy individuals, they might not be very well 
adapted to escape host immunity from healthy individuals. Infected individuals 
with an intermediate level of immunity (i.e. elderly, malnourished) may have 
the optimal intermediate level of immune suppression to generate a complex 
quasispecies and drive virus evolution. A recent study tried to investigate the 
hypothesis whether immunocompromised individuals could be a source of 
new GII.4 variants and concluded that rapidly evolving norovirus populations 
among immunocompromised host do not significantly contribute to the overall 
norovirus evolution[30]. This conclusion is based on a mathematical SIRS model 
that estimates the contribution of the immunocompromised and immunocom-
petent subpopulations to the overall pathogen evolution. A sensitivity analysis 
(testing different scenarios) was performed to determine the robustness of the 
model, especially for parameters with large uncertainty like the norovirus basic 
reproduction number, duration of immunity, and proportion of immunocom-
promised patients. The authors finally conclude that: “…,despite an increased 
rate of nucleotide substitution and an extended duration of infection, the 
rarity of immunocompromised hosts in the population limits their influence to 
broader NoV dynamics, which are still dominated by the lower evolutionary 
rates apparent in the general population”[30]. Or in other words: the immuno-
compromised population is too small compared to the immunocompetent 
population, to have an effect on the overall norovirus evolution – even with very 
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high mutation rates and long lasting infections as found in chronic shedders. 
There are some problems with this conclusion. Viral population dynamics are 
extremely complex and each individual mutation can have an effect on the viral 
life cycle, receptor specificity, transmission efficiency, viral fitness, or stability of 
virus particles, but the mathematical model used by the authors did count each 
mutation equal, which is an extreme simplification of the processes underlying 
virus population dynamics. Furthermore, it is not the accumulated genetic 
diversity among all immunocompromised individuals in the population that 
forms a new GII.4 variant as suggested by the model of the authors, but a very 
rare event that only occurs in an individual patient every 2-3 years somewhere in 
the world. Thus the authors used unsuitable methods to study this hypothesis 
in my opinion, and future studies using sequence confirmation are needed to 
determine the transmissibility of new variants found in immunocompromised 
individuals as suggested earlier.
Recombination due to template switching of the RNA dependent viral 
polymerase (RdVP) is another important driving force of norovirus evolution and 
occurs most frequently at the ORF1/ORF2 breakpoint[31]. Novel recombinants, 
like the GII.P16 - GII.4 Sydney 2012, originate from hosts infected by multiple 
norovirus strains. Foodborne outbreaks are often caused by a mixture of strains 
and are therefore a potential source of novel recombinant strains[32]. Long 
lasting infections, as recently observed in immunocompromised patients, may 
also constitute a risk for recombination events since these patients could easily 
obtain a secondary infection. 
Implications for vaccine development
Two vaccine candidates are currently in phase I and II clinical trials: an 
intramuscular bivalent vaccine based on GI.1 and GII.4 virus like particles 
(VLP) (Takeda vaccines, Tokyo, Japan) and a monovalent oral vaccine based on 
GI.1 virus protein 1 (VP1) (Vaxart, San Francisco, USA)[33]. The efficacy of the 
monovalent vaccine has not been tested yet and two doses of the intramuscular 
bivalent vaccine was shown to reduce the risk for getting gastroenteritis 
with 32% towards a homologous strain in a randomized, double-blind, 
placebo-controlled study[34]. The bivalent vaccine has a protective effect to a 
homologous strain under ideal circumstances, but it is less effective than the 
vaccine effectiveness of the currently licensed influenza vaccine, and shows that 
norovirus vaccine development is complex and that significant improvements 
need to be made before the vaccine can be accepted on the market. It further 
remains to be determined how long the vaccine provides protection, how 
efficacious it is in individuals with a diminished immune system (e.g. elderly 
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people), and whether it can provide protection against heterologous strains. 
Heterologous protection is of major importance since multiple norovirus 
genotypes are circulating within the human population simultaneously as 
shown in chapter 3 and since it is likely not feasible to include all known 
human genotypes in the vaccine due to related high costs. We only have limited 
understanding of the human immune response and the level of protection 
upon natural norovirus infection. Some studies suggest that natural infection 
with a genotype protects with limited duration against (symptomatic) infection 
with other genotypes of the same genogroup (within genogroup heterologous 
protection), while other studies could not repeat these results, potentially due 
to a limited studied population size[35-37]. A birth cohort study from Peru found 
that repeated infections with a genotype of the same genogroup were common 
within a 2-year time span, but repeated infections with the same genotype were 
rare[38]. Patterns of norovirus immune protection are complex and may resemble 
patterns of antigenic relatedness rather than genetic similarity at the genogroup 
level. Prospective studies need to address whether natural infection protects 
from subsequent infection with heterologous genotypes, and whether current 
vaccine candidates can simulate natural infection. Norovirus vaccine design 
should take into account that major changes in the norovirus epidemiology 
require major and time constrained updates of the antigenic composition of the 
vaccine, especially if heterologous immune protection is not feasible with current 
vaccine technology. A recent study showed that IgA antibodies better block 
norovirus binding to histo-blood group antigens than their IgG isotype-switched 
variants[39]. Thus mucosal IgA may play a key role in immunity to norovirus and 
new adjuvants and novel administration techniques could potentially improve 
mucosal immunity to norovirus and therefore enhance the efficacy of the 
vaccine[40, 41]. Norovirus vaccine research has always been hampered by the lack 
of a cell culturing system, which prohibited the development of neutralization 
assays to study immune correlates of protection. HBGA blocking assays using 
virus like particles (VLPs) are used as a surrogate, and have been useful to 
get a better understanding of factors influencing binding of norovirus to the 
host cell HBGAs, but may not fully correlate with protection from disease[42]. 
The discovery that human noroviruses can be cultured in B cells is a recent 
breakthrough in the norovirus research field and an important finding on the 
road to an effective norovirus vaccine on the market[43, 44].
Future perspective on chronic shedders
Norovirus infection is common among immunocompromised individuals and 
can become a chronic infection as shown in chapter 5 and 6. Patients with 
chronic norovirus infection shed virus in extremely high quantities for multiple 
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years. An important and not well studied question is whether chronic norovirus 
infection causes a symptomatic or asymptomatic infection. Symptoms of 
gastroenteritis are known to be common among the immunocompromised 
patient populations and can have multiple causes, including immunosuppressive 
treatment, host-versus-graft disease, viral, bacterial or parasitic infections, or a 
combination of these. Norovirus infection has always been considered to be an 
acute disease and of short-term duration, and therefore not related to persistent 
symptoms of gastroenteritis. The symptoms of the patients enrolled in our 
studies were not systematically recorded since both studies were retrospective, 
and we could only retrieve symptoms from the hospital medical patient record 
database. However, some of the patients enrolled in our studies were positive 
for norovirus and reported to have long-term and/or severe complaints of 
gastroenteritis corresponding to the period of norovirus shedding, suggesting 
that norovirus was the causative agent. Two other studies recently reported 
severe diarrheal disease among immunocompromised patients related to 
norovirus infection, which indicates that this is an under recognized syndrome 
which potentially highly affects the quality of life of already severely ill patients[45, 
46]. Future studies need to determine the incidence of long-term gastroenteritis 
among the norovirus infected immunocompromised patient population. Higher 
awareness among clinicians and frequent sampling could distinguish norovirus 
related diarrhoea from other causes of diarrhoea, and help to guide treatment. 
Treatment options include reduction or modification of the immunosuppressive 
therapy, experimental immunoglobulin treatment), and possibly off label 
nitazoxanide treatment[47-50]. Novel antiviral compounds are furthermore under 
development[51-53]. 
An important question for hospital hygiene and infection control guidelines is 
whether noroviruses found in immunocompromised patients are transmissible 
to other patients or the general population. Immunocompromised patients with 
norovirus infection are not isolated from other patients in the current hospital 
practice, as suggested earlier for all viral pathogens causing gastroenteritis[54]. 
Chronic shedders shed virus in extremely large quantities and, given the low 
infectious dose required to induce infection, it is not unlikely that these patients 
transmit the virus to e.g. other immunocompromised patients in the hospital. 
Evidence on the transmission of norovirus between immunocompromised 
patients is scarce since this question has not been systematically studied. We 
therefore advocate to enhance surveillance in this vulnerable patient population. 
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Concluding remarks
In conclusion, the norovirus genetic diversity is continuously evolving and 
the global dominance of GII.4 for at least two decades is under pressure. 
The observed changes in the norovirus molecular epidemiology with frequent 
emergence of GII.4 drift variants, emergence of novel recombinants, and 
predominant genotype switches require a norovirus vaccine that can be 
easily updated within a limited time span. The drift variants observed among 
immunocompromised individuals may constitute a risk for other immunocom-
promised individuals and might be a reservoir of new norovirus variation for 
the general population. Future studies need to address the risk of transmission 
between immunocompromised individuals and between immunocompromised 
individuals and healthy individuals. Immunocompromised individuals with 
chronic norovirus infection may suffer from persistent symptoms of diarrhoea 
with a consequent serious loss of quality of life, and future studies need to 
address the severity and incidence of chronic diarrhoea and how these patients 
can be treated to eliminate infection. 
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Summary
Summary
Noroviruses belong to the family of Caliciviridae and cause acute gastroenteritis. 
The genetic diversity within the genus Norovirus is extremely large and novel 
genotypes, recombinants within and between genotypes, and antigenic drift 
variants are regularly discovered. The distribution and incidence of norovirus 
genotypes changes over time and by geographic region, with GII.4 as the 
predominant genotype responsible for approximately 70% of the outbreaks 
detected worldwide. This thesis contributes to a better understanding of the 
global norovirus diversity, and the role of chronic norovirus infection among 
immunocompromised individuals on virus diversity, antigenic variation and 
evolution. We describe the emergence of a novel GII.4 drift variant and novel 
GII.17 in chapter 2.1 and 2.2, respectively. Chapter 3 provides an overview of the 
global norovirus molecular epidemiology using data obtained by the NoroNet 
surveillance network in the last ten years. Chapter 4 shows that GII.4 was not 
predominant before the wide spread use of norovirus molecular typing methods 
in the mid-1990s. Chapter 5 shows that chronic norovirus infection is common 
among solid organ transplant patients and more than doubled the number of 
described patients in literature. Finally, chapter 6 shows that virus populations 
in the immunocompromised host are genetically distinct from viruses circulating 
in the general population. These hosts therefore may contain a reservoir of newly 
emerging strains and future studies need to address whether these new strains 
can be transmitted to other immunocompromised patients or individuals in 
the general population. Norovirus vaccines are currently tested in clinical trials. 
The observed global changes in the norovirus molecular epidemiology require a 
norovirus vaccine with broad immune protection and an antigenic component 
that can be easily updated within a limited time span. Immunocompromised 
patients with chronic norovirus infection may suffer of persistent symptoms of 
diarrhoea with a consequent severe loss of quality of life and future studies need 
to address how these patients can be treated to eliminate infection.
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Norovirussen behoren tot de familie Caliciviridae en veroorzaken acute 
gastro-enteritis. De genetische diversiteit van het genus Norovirus is extreem 
groot en nieuwe genotypes, recombinanten binnen en tussen genotypes, en 
drift varianten worden regelmatig ontdekt. De geografische verspreiding en 
incidentie van norovirus genotypes veranderen in de tijd, waarbij genogroup II 
genotype 4 (GII.4) het meest voorkomende genotype is en verantwoordelijk voor 
ongeveer 70% van de uitbraken wereldwijd. Deze thesis draagt bij aan een beter 
begrip van de wereldwijde genetische diversiteit van norovirussen, en de rol van 
chronische infectie bij patiënten met een immuundeficiëntie op de virusdiver-
si teit, de antigene variatie en de evolutie. We beschrijven de uitbraak van een 
nieuwe GII.4 drift- variant en een nieuwe GII.17 in respectievelijk hoofdstuk 
2.1 en 2.2. Hoofdstuk 3 geeft een overzicht van de wereldwijde moleculaire 
epidemiologie van norovirussen met data verzameld via het NoroNet netwerk 
in de afgelopen tien jaar. Hoofdstuk 4 laat zien dat GII.4 niet het meest 
voorkomende genotype was voor het wijdverspreide gebruik van moleculaire 
typerings methodes in het midden van de jaren negentig. Hoofdstuk 5 laat zien 
dat een chronische norovirus infectie algemeen is bij orgaantransplantatie-
patiënten en deze studie verdubbelde het aantal in de literatuur beschreven 
patiënten ruim. Ten slotte laat hoofdstuk 6 zien dat virus populaties bij 
patiënten met een immuundeficiëntie genetisch afwijken van de virussen die 
worden gevonden in de algemene populatie. Deze patiënten zijn daardoor 
mogelijk een reservoir van nieuwe uitbraakstammen. Toekomstige studies 
moeten uitwijzen of deze virusstammen kunnen worden verspreid naar andere 
patiënten of individuen in de algemene bevolking. Norovirus vaccins worden 
momenteel getest in klinische studies. De geobserveerde veranderingen in de 
moleculaire epidemiologie vragen om een norovirus vaccin met brede immuun-
bescherming en een makkelijk en snel aan te passen antigene component. 
Patiënten met een immuundeficiëntie en een chronische norovirus infectie 
hebben mogelijk last van chronische diarree met ernstige gevolgen voor de 
kwaliteit van leven en toekomstige studies moeten uitwijzen hoe deze patiënten 
het beste behandeld kunnen worden om van de infectie te genezen. 
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van Amersfoort en meer recent in de boulder- en klimhallen van Helsinki. Ik wil 
alle klimmers bedanken waarmee ik in de afgelopen jaren geklommen heb. 
Job en Hilde, bij jullie ben ik echt altijd welkom voor heerlijk eten, om 
knapperige pizza’s te bakken, cappuccino in de tuin te drinken, lekkere koekjes 
en taart te eten, een warm bed, een gezellig gesprek of een glas whisky. Dank 
voor alle gezellige momenten. Ik wil Dries en Marieke bedanken voor de 
gezellige etentjes, en Tako voor lange wandelingen met goed gesprek in het bos. 
Salla and Elina, I am happy we met, thank you for your hospitality, explanation 
about Finnish culture, and climbing trips. 
En dan mijn lieve familie, zonder jullie zou ik hier niet staan. Dit proefschrift 
was al heel lang bijna af en jullie hebben al die tijd met veel geduld en interesse 
naar mijn verhalen geluisterd. Lieve ouders, dank voor jullie onvoorwaardelijke 
steun, warme betrokkenheid en vertrouwen in al die jaren dat we samen zijn. 
Jullie staan altijd voor me klaar, zelfs in het verre en koude Helsinki. Lieve Tessa 
en Dennis, ook jullie staan altijd voor me klaar. Dank voor jullie steun, gezellige 
tijd, en leuke vakanties. Lieve Benjamin en Noa, van jullie gekke bekken voor 
de iPad en schaterlach word ik heel blij. Leuk dat jullie er zijn en dank voor de 
afleiding!
Janko 
Helsinki, februari 2018
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